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Abstract 
The microtubule network is involved in cellular processes including protein 
transport and cell division. Microtubule stabilising drugs (MSD) bind to 
microtubules and alter their dynamic balance in favour of the polymerised state. 
While primarily known for their anti-mitotic properties, MSD also exert 
immunomodulatory effects in vitro and in vivo. It is the aim of this project to 
investigate the effects of MSD on protein trafficking and secretion to determine 
how they affect immune-mediated exocytosis.  
 
Previous work in our lab demonstrated that macrophage responses to bacterial 
lipopolysaccharide, as measured by the production of TNF-α and nitric oxide, are 
inhibited by both paclitaxel and peloruside. In this thesis we continued this work 
and saw that inhibition was not affected by temporal IFN-γ priming and found that 
altered production kinetics were not sufficient to explain the inhibition. 
 
To kill target cells cytotoxic T cells (CTL) reorganise their cytoskeleton so that lytic 
granules can traffic down microtubules to be delivered to the target. Using an in 
vitro model of CTL killing, we saw that MSD did not inhibit killing by CTL, lytic 
granule delivery to the cell surface, or antigen-stimulated Interferon-γ (IFN-γ) 
production by CTL. In contrast to this, in a murine model of antigen-induced killing 
we saw that a single dose of paclitaxel had a significant inhibitory effect on CTL-
mediated cytolysis in vivo. 
 
Together these studies suggest that MSD have multiple immunomodulatory 
effects that are independent of their anti-proliferative effects. The data suggest 
that patients undergoing taxane therapy may be unable to fight infection long 
before the anti-mitotic effects of MSD are apparent. 
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1. General Introduction 
1.1 Microtubules & Microtubule Associated Drugs: 
1.1.1 Microtubule Structure and Function 
 
Microtubules are an essential and dynamic component of the cytoskeleton and 
are involved in many intracellular processes. Microtubules help maintain cellular 
structure and are involved in cellular transport, exocytosis, polarisation, migration, 
adhesion and cell division (Bacallao et al., 1989; Dvorak et al., 2002; Ezratty et 
al., 2005; Hirokawa, 1998; Jordan et al., 1993; Kaverina et al., 1998; Kuncl et al., 
2003; Presley et al., 1997; Vasiliev et al., 1970; Yeh et al., 1995; Yisraeli et al., 
1990). They consist of α/β-tubulin heterodimers that stack into linear 
protofilaments, typically thirteen of which associate laterally and fold into 25 
nanometer cylindrical tubes (Desai and Mitchison, 1997; Li et al., 2002; Löwe et 
al., 2001; Nogales et al., 1998). At one end microtubules are bordered by a ring of 
α-tubulin and at the other by a ring of β-tubulin, known respectively as the minus-
end and the plus-end (Nogales et al., 1999). Both α- and β-tubulin possess 
guanine nucleotide binding sites, but in α-tubulin guanosine triphosphate (GTP) 
binds this site irreversibly (Nogales et al., 1998). This irreversibile GTP binding, 
together with associating Mg2+ ions, microtubule associated proteins and 
stabilisation by the microtubule organising centre (MTOC) makes the minus-end a 
relatively stable structure (Drechsel et al., 1992; Menendez et al., 1998; Piel et al., 
2000). Conversely, the β-subunit guanine nucleotide binding site is exchangeable; 
GTP is hydrolysed to guanosine diphosphate (GDP) as new heterodimers bind to 
and lengthen the microtubule (Löwe et al., 2001; Nogales et al., 1999; Nogales et 
al., 1998). Microtubules with GTP-bound β-tubulin exposed at the plus-end favour 
a straight protofilament conformation which promotes polymerisation, whereas 
GDP-bound tubulin adopts a curved conformation promoting depolymerisation 
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(Nogales et al., 1998). As GTP is only hydrolysed on heterodimer addition, the 
exposed plus-end is stable. However, when GDP-bound tubulin is exposed the 
conformational change induces depolymerisation (Desai and Mitchison, 1997; 
Nogales et al., 1999; Walker et al., 1989). Rapid switching between phases of 
microtubule growth and decay, termed “dynamic instability”, is an important part of 
cellular microtubule function (Blocker et al., 1998; Desai and Mitchison, 1997; 
Jordan et al., 1993). As well as processes dependent on dynamicity, MAPs, such 
as kinesin and dynein, use the microtubule network as a scaffold to move proteins 
towards the plus-end and minus-end of microtubules, facilitating rapid transport 
(up to 1.5 µm/s) around the cell (Gibbons, 1981; Presley et al., 1997; Vale et al., 
1985). Two classes of compound elicit their effects by altering the microtubule 
network – Microtubule destabiling drugs (DSD), and microtubule stabilising drugs 
(MSD). Altering the structure and dynamicity of microtubules has wide-reaching 
physiological effects and it was the aim of this thesis to understand how 
modification by microtubule actives affects the immune system.  
1.1.2 Microtubule Destabilising Drugs 
 
DSD interact with microtubules in numerous ways, all of which have the net effect 
of reducing microtubule dynamicity by destroying the microtubule network (Jordan 
and Wilson, 2004; O'Brien Jr et al., 1995). These drugs have been successfully 
employed as anti-cancer or anti-inflammatory drugs (Ahern et al., 1987; Nole et 
al., 2009). DSD commonly used in the laboratory are colchicine, the vinca 
alkaloids (vincristine, vinblastine and vinorelbine), nocodazole and 
podophyllatoxin (Ding et al., 1990a). 
1.1.3 Microtubule Stabilising Drugs 
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In contrast to DSD, MSD have the ability to bind to and stabilise microtubules. 
At low concentrations this suppresses dynamic instability, and at higher 
concentrations the structural arrangement of the network is altered (Hood et al., 
2002; Jordan et al., 1993; Jordan and Wilson, 2004; O'Brien Jr et al., 1995). MSD 
cause mitotic block, the appearance of multiple mitotic asters, and the induction of 
apoptosis in dividing cells as well as cause microtubule bundling in interphase 
cells (Hood et al., 2002; Jordan et al., 1993; O'Brien Jr et al., 1995). Such drugs 
have been applied as chemotherapeutics and are still in wide clinical use. MSD 
include paclitaxel, docetaxel, the epothilones, TTI-237, discodermolide, 
laulimalide and peloruside A (peloruside) (Beyer et al., 2008; Buey et al., 2005; 
Mooberry et al., 1999; West et al., 2000). The microtubule stabilising activity of 
paclitaxel and peloruside are discussed in more detail below. 
1.1.3.1 Paclitaxel 
 
The first discovered MSD, paclitaxel, was isolated from the pacific yew tree Taxus 
brevifolia (Schiff et al., 1979; Wani et al., 1971). Low nanomolar concentrations of 
paclitaxel induce apoptosis and cause mitotic block at the G2/M-phase transition 
of the cell cycle and induce bundling in interphase cells (Jordan et al., 1993; Schiff 
et al., 1979). Paclitaxel binds to the taxane site on microtubules, a site shared by 
most other MSD (Buey et al., 2005; Nogales et al., 1998). Paclitaxel, marketed as 
Taxol®, is used clinically to treat a wide range of solid tumour cancers, including 
breast, endometrial and non-small cell lung carcinoma (Connelly et al., 1996; 
Holmes et al., 1991; Kelly et al., 2001). Some cancers are resistant to a broad 
spectrum of chemotherapeutic agents, including paclitaxel, which is associated 
with overexpression of the MDR-1 gene encoding the P-glycoprotein efflux pump 
(P-gp) (Gaitanos et al., 2004; Goldstein et al., 1989; Newman et al., 2000; Parekh 
et al., 1997). Further, due to limited solubility, paclitaxel is administered using 
Cremophor EL® as a vehicle which is associated with deleterious side effects 
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(Gelderblom et al., 2001; Goldstein et al., 1989; Newman et al., 2000; Parekh et 
al., 1997). Due to limitations of delivery and multi-drug resistance, alternative MSD 
and delivery mechanisms for paclitaxel are currently under development.  
1.1.3.2 Peloruside  
 
A recently discovered MSD, peloruside, was isolated from the New Zealand 
marine sponge Mycale hentscheli (West et al., 2000). Like paclitaxel, peloruside 
causes mitotic block at low nanomolar concentrations and induces microtubule 
bundling at higher concentrations (Crume et al., 2007; Gaitanos et al., 2004; Hood 
et al., 2001; Hood et al., 2002; Miller et al., 2004; Wilmes et al., 2007). Peloruside 
binds to a site on microtubules distinct from the taxane site that shows overlap 
with laulimalide (Gaitanos et al., 2004; Hamel et al., 2006; Huzil et al., 2008). The 
compound is a potent inducer of apoptosis in P-gp-expressing cell lines and 
synergises with a number of taxane-site MSD in the polymerisation of tubulin and 
killing of cell lines in vitro (Gaitanos et al., 2004; Hamel et al., 2006; Wilmes et al., 
2007). Currently, it shows great promise for development as an alternative 
chemotherapeutic agent to paclitaxel. 
1.1.4 In vivo Immunomodulation by Microtubule Stabilising Drugs 
 
As mentioned in section 1.1.3, MSD are used clinically in the treatment of a 
variety of cancers. Chemotherapy involving taxanes (paclitaxel or docetaxel) can 
substantially modify the human immune system. First and foremost, the agents 
cause general leukopenia (Tong et al., 2000). CD8+ T cells, however, survive 
better than other lymphocyte subsets and replenish comparatively faster post-
therapy (Westerterp et al., 2008; Zhang et al., 2008). Increased numbers of IFN-
γ+- and activated CD44High-CD8+ T cells have also been reported following taxane 
therapy (Zhang et al., 2008). In contrast, paclitaxel causes a selective inhibitory 
effect on TREG function (Zhang et al., 2008). Taxane therapy also modifies the 
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cytokine environment of cancer patients, suggesting that MSD induce a variety 
of effects on the immune system (Penson et al., 2000; Tong et al., 2000; Tsavaris 
et al., 2002; Zhang et al., 2008).  
 
Recent investigations in mice combining immunotherapies with taxane treatment 
have consistently found positive effects of the combined therapy on tumour 
regression (Chu et al., 2006; Emens et al., 2001; Yu et al., 2003; Zhong et al., 
2007). These positive outcomes are associated with decreased TREG function and 
increased anti-tumour cytotoxic T lymphocyte (CTL) responses (Chu et al., 2006; 
Garnett et al., 2008; Vicari et al., 2009; Yu et al., 2003; Zhong et al., 2007). It is 
apparent that MSD can alter the immune system, but few studies distinguish 
functional modifications to immune cells caused by MSD from anti-proliferative 
properties. The immune responses of macrophages (MØ) and cytotoxic T 
lymphocytes (CTL) involve microtubules either after or without entering mitosis, 
making it possible to investigate the functional effects of MSD on these cell types. 
1.2 Macrophage function: Role and Responses 
1.2.1 Macrophage Function 
MØ are terminally-differentiated phagocytic cells of the innate immune system. 
MØ are one of the first cells to respond to infection and act predominantly through 
pattern recognition receptors, such as the toll-like receptors (TLR). TLR recognise 
conserved carbohydrate, nucleic acid and lipotechoic acid motifs, collectively 
termed pathogen-associated molecular patterns (PAMP) (Akira et al., 2001). One 
of the major receptors involved in MØ responses is TLR-4, which is stimulated by 
bacterial lipopolysaccharide (LPS) (Akira et al., 2001; Hirschfeld et al., 2000). 
Optimal activation of TLR-4 is conferred when TLR-4 associates with MD-2, 
CD14, and LPS-bound LPS-binding protein to form the TLR-4 signalling complex 
(da Silva Correia et al., 2001; Wright et al., 1990). Stimulation of the TLR-4 
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complex by LPS causes MØ to produce high levels of the proinflammatory 
mediators TNF-α, IL-1β, IL-6, IL-8, IL-12p40, MMP-9, and nitric oxide (NO); to 
upregulate MHC-II; and also alters tissue trafficking of the cells (Chow et al., 1999; 
Crume et al., 2007; Fiorentino et al., 1991; Hirschfeld et al., 2000; Hoshino et al., 
1999; Kawai et al., 1999; Kincy-Cain and Bost, 1997; Marikovsky et al., 2003; 
Nakano et al., 1999; Schartner et al., 2005; Stuehr and Marletta, 1985; Tamandl 
et al., 2003; Tobias et al., 1993; Woo et al., 2004; Xie et al., 1994). Priming MØ 
with IFN-γ augments production of these mediators. Most importantly, pre-
treatment with IFN-γ enhances production of TNF-α and NO in response to LPS 
(Ding et al., 1988; Gifford and Lohmann-Matthes, 1987; Stuehr and Marletta, 
1985). Furthermore, IFN-γ also synergises with TNF-α to enhance the production 
of NO (Vila-del Sol et al., 2006). 
1.2.2 Tumour Necrosis Factor-α  
 
TNF-α signalling is important in the host response to infection, functioning as both 
a signalling molecule and an inducer of apoptosis (Carswell et al., 1975; Havell, 
1989; Rothe et al., 1993). TNF-α is an early onset cytokine that is rapidly 
produced by LPS-activated MØ. TNF-α mRNA can be detected in MØ as little as 
30 minutes after LPS activation and most protein production occurs in the first 2-
10 hours (Crume et al., 2007; Sander et al., 1991; Takasuka et al., 1995). 
Prolonging culture generally leads to decreases in bioactive protein (Fujihara et 
al., 1994; Virca et al., 1989). It was first identified as an LPS activation product 
with tumoricidal properties, and later as a chemotactic agent capable of inducing 
migration of monocytes and neutrophils (Carswell et al., 1975; Ming et al., 1987). 
There are two signalling receptors for TNF-α: TNF-RI and TNF-RII. While both 
TNF-RI and TNF-RII stimulate proinflammatory immune signalling through nuclear 
factor–κβ (NF-kβ) and c-Jun N-terminal kinase (JNK)/MAP-kinase (MAP-K) 
pathways (Liu et al., 1996; Tartaglia et al., 1993), TNF-RI is the predominant 
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effector of apoptosis in non-haematopoetic cells (Beg and Baltimore, 1996; 
Vandenabeele et al., 1995a). TNF-RI expresses a cytoplasmic death domain 
signal sequence which activates the caspase cascade (Nagata, 1997; Wang et 
al., 1998). However, NF-kB signalling blocks TNF-α-induced apoptosis and is thus 
anti-apoptotic (Beg and Baltimore, 1996; Wang et al., 1998). In contrast to TNF-
RI, TNF-RII lacks the cytoplasmic death domain, and while it synergises with TNF-
RI in the induction of apoptosis (Vandenabeele et al., 1995b), TNF-RII is primarily 
involved in immune signalling (Rothe et al., 1994).  
 
Recently it has been identified that secretion of TNF-α occurs in a unique fashion, 
as it associates with recycling endosomes. When MØ are activated, these 
endosomes fuse with the plasma membrane facilitating rapid release of TNF-α 
(Manderson et al., 2007; Murray et al., 2005). Once released, as NF-kβ activation 
stimulates TNF-α gene transcription, TNF-α can enhance its own production 
(Collart et al., 1990).  
1.2.3 Nitric Oxide 
 
Like TNF-α, NO is involved in the host response against microbial infection 
(Stenger et al., 1996). NO is produced by the enzyme nitric oxide synthase (NOS). 
Three distinct isoforms of NOS exist – neuronal NOS (nNOS; NOS1), inducible 
NOS (iNOS; NOS2) and endothelial NOS (eNOS; NOS3) (Bredt et al., 1991; 
Marsden et al., 1992; Xie et al., 1992). nNOS and eNOS are constitutively active 
and produce NO in a calcium dependent manner, but operate in different tissue 
types and have different functions to iNOS (Alderton et al., 2001; Bredt and 
Snyder, 1989, 1990; Janssens et al., 1992). Immune-mediated NO production 
occurs primarily via iNOS which has a minimal requirement for calcium and can 
induce much higher levels of NO than nNOS or eNOS (Lowenstein et al., 1992; 
MacMicking et al., 1997; Stuehr and Marletta, 1985; Xie et al., 1992). While IFN-γ 
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alone can induce iNOS mRNA activity, both LPS and TNF-α synergise with IFN-
γ to enhance NO production (Ding et al., 1988; Geller et al., 1993; MacMicking et 
al., 1997). Compared to TNF-α, NO production occurs relatively later following 
LPS-activation, and is typically measured at later timepoints (Crume et al., 2007; 
Vila-del Sol et al., 2006).  
1.2.4 Paclitaxel is a LPS Mimetic 
 
Unique among MSD, paclitaxel mimics LPS in vitro by activating murine MØ to 
produce proinflammatory mediators including IL-1β, IL-12p40, TNF-α and NO 
(Bogdan and Ding, 1992; Crume et al., 2007; Ding et al., 1990b). Like LPS, 
paclitaxel-induced inflammation is dependent on signalling through the TLR-4 
complex and is blocked in LPS-hyporesponsive and TLR-4-/- mice, as well as by 
antagonists of TLR-4 activation (Byrd-Leifer C.A. et al., 2001; Ding et al., 1992; 
Hoshino et al., 1999; Kawasaki et al., 2000; Manthey et al., 1993; Perera et al., 
2001). No other MSD, including peloruside and the semi-synthetic paclitaxel 
analogue docetaxel, share this mimicry (Crume et al., 2007; Manthey et al., 1993). 
Importantly, paclitaxel specifically stimulates murine TLR-4/MD-2 and does not 
activate human monocytes or MØ (Allen et al., 1993), or cells transfected with 
human MD-2 (Kawasaki et al., 2000; Kawasaki et al., 2001).  
 
Some work investigating the TLR-4-mediated effects of paclitaxel on LPS-
tolerance has been conducted. LPS-tolerance is a state in which MØ responses to 
LPS are altered if the MØ have previously been exposed to low concentrations of 
LPS (Takasuka et al., 1991). The low-dose LPS-priming depresses transcriptional 
activity and alters the proinflammatory cytokine response (Shnyra et al., 1998; 
Tominaga et al., 1999). Most significantly, LPS-primed MØ are reciprocally 
rendered predominant producers of either TNF-α or NO, relating directly to the 
priming dose of LPS (Hirohashi and Morrison, 1996; Shnyra et al., 1998; Zhang 
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and Morrison, 1993a, b). In a similar fashion, when MØ are pretreated with 
either LPS or paclitaxel, paclitaxel-induced TNF-α production is reduced, and the 
production of NO is reciprocally enhanced (Nakano et al., 1999). Further studies 
show that paclitaxel, likely due to its TLR-4 mimicry, depresses NF-kB and MAP-K 
phosphorylation in LPS-tolerant MØ (Tominaga et al., 1999), and a similar state of 
tolerance is induced by paclitaxel on LPS responses in B-cells (Lee and Jeon, 
2001; Lee et al., 2000). 
1.2.5 Involvement of the Microtubule Network in LPS Signalling 
 
Activation of the TLR-4 complex by paclitaxel has been heavily investigated, but 
only a small body of literature has examined the combined effects of simultaneous 
exposure to LPS and microtubule actives on TLR-4 responses. The most recent 
studies by our group investigated the effects of paclitaxel and peloruside on IFN-
γ-primed murine bone-marrow derived MØ (BMMØ) and demonstrated that while 
peloruside does not activate TLR-4 like paclitaxel, both peloruside and paclitaxel 
inhibit LPS-induced TNF-α and NO production (Crume et al., 2007). Earlier work 
using LPS-activated peritoneal MØ (PMØ) assessed only low concentrations of 
paclitaxel that did not inhibit TNF-α production, but did not assess higher 
concentrations which may have revealed an effect (Manthey et al., 1992). 
 
Similar effects on LPS-induced cytokine production are seen with DSD. DSD 
diminish LPS-induced TNF-RI expression, TNF-α protein production, iNOS activity 
and NO production in PMØ (Ding et al., 1990b; Kirikae et al., 1996; Li et al., 
1996). In the RAW MØ cell line, LPS-induced production of TNF-α and GM-CSF 
are inhibited, but in contrast to PMØ, iNOS activity is unaltered (Isowa et al., 1999; 
Rao et al., 1997). Thus murine MØ responses to LPS are similarly inhibited by 
DSD and MSD. 
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In general, DSD & MSD affect human and murine MØ similarly, but some 
differences between species do occur. Studies into DSD show that colchicine 
inhibits LPS-induced peripheral blood mononuclear cell (PBMC) TNF-α 
production, but enhances IL-1β production (Allen et al., 1991). Similar inhibitory 
effects of the DSD nocodazole on IL-1β and TNF-α are observed in PMA-
stimulated human monocytes (Rammes et al., 1997). Interestingly, while paclitaxel 
does not directly activate human TLR-4 (Kawasaki et al., 2000; Resman et al., 
2008), in the presence of paclitaxel, PBMC production of both IL-1β and TNF-α 
are increased (Allen et al., 1993). This is the opposite effect of paclitaxel on TNF-
α production to that seen in murine BMMØ (Crume et al., 2007), and the opposite 
effect on TNF-α production from DSD (Allen et al., 1991).  
  
Here, it is apparent that species and cell type can lead to different effects of 
microtubule actives on cytokine production. Microtubules are involved in almost 
every facet of cellular function (section 1.1.1) so targeting them causes relatively 
non-specific pathway inhibition. It is the combined effect of all such modified 
interactions that render the final phenotype; altering the microtubule network can 
have drastic consequences on the inflammatory response. With this in mind, it is 
important to understand the pathways that are most crucial for immune signalling 
that we may better understand the immunological implications of MSD therapy. 
1.3 CD8+ T Cells: Activation & CTL-Mediated Cell Death 
 
1.3.1 The role of CD8+ T Cells 
 
Cytotoxic T lymphocytes (CTL) are cells of the adaptive immune system that 
function primarily to kill virally-infected and cancerous cells (Abougergi et al., 
2005; Breart et al., 2008; Kagi et al., 1994; Shimizu et al., 1999). Naïve CD8+ T 
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cells are the precursors to CTL, both of which express T cell receptors (TCR) 
specific for the same short peptide presented in the context of MHC-I (Townsend 
et al., 1986). Such short peptides are termed „antigens‟ (Janeway et al., 2001). 
Typically the TCR repertoire of an individual mouse or human is enormous and 
allows the immune system to direct responses against pathogens expressing 
many different antigens. However, transgenic mice have been generated that 
express limited and peptide-specific TCR. For example, OT-I mice are modified 
such that a large proportion of T cells express CD8 and Vα2/Vβ5.1/5.2-TCR that 
recognise the SIINFEKL peptide of OVA protein, allowing for great enrichment of 
these T cells and tight control of the experimental immune response (Hogquist et 
al., 1994). 
 
For both normal and transgenic CD8+ T cells, recognition of the TCR-specific 
antigen in the context of MHC-I is required to activate the T cell and generate an 
effective immune response. To differentiate into effector CTL, naïve CD8+ T cells 
encountering an antigen presenting cell (APC) in the lymph node scan the APC 
surface for antigen-MHC-I complexes. When the specific antigen is recognised, 
formation of a signalling complex including the TCR, MHC-I, CD8 and 
costimulatory molecules activate the T cell (Albert et al., 1998; Bachmann et al., 
1997; Cottalorda et al., 2006; Luescher et al., 1995). This leads to large-scale 
proliferative expansion and activation of the CD8+ T cell population (Tanchot et 
al., 1997). 
 
As the CD8+ T cells replicate they undergo characteristic functional changes that 
alter their activity and tissue homing properties. Immature, antigen inexperienced, 
naïve CD8+ T cells are required to divide at least once to reach effector status, 
both in vitro and in vivo (Oehen and Brduscha-Riem, 1998). During progressive 
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divisions, the lytic machinery of the CD8+ T cell is upregulated and the cells 
increase in cytolytic capacity (Oehen and Brduscha-Riem, 1998; Wolint et al., 
2004). With later cell divisions, CTL granule potency reduces, and the CTL 
develop into a memory phenotype (Oehen and Brduscha-Riem, 1998).  
 
The effector status of CD8+ T cells can be determined by surface markers 
involved in tissue homing and intercellular recognition (Table 1.1). In vivo, naïve 
CD8+ T cells are stereotypically CD44low, CD45RA+, CD62Lhigh, and CD69low 
(Hamann et al., 1997; Oehen and Brduscha-Riem, 1998). After antigenic 
stimulation, naïve CD8+ T cells immediately upregulate CD69 and integrins, and 
begin to divide (Hamann et al., 1997; Oehen and Brduscha-Riem, 1998). It takes 
at least 24 hours for CD8+ T cells to divide and become CTL capable of rapidly 
killing target cells (Boissonnas et al., 2004; Hwang et al., 2006; Oehen and 
Brduscha-Riem, 1998). CTL are characteristically CD44High, CD62LLow,  and 
express reduced levels of TCR as well as increased levels CD25 (Oehen and 
Brduscha-Riem, 1998). Further divisions convert the CTL population into a 
memory phenotype. Two related classes of memory T cells exist – Effector 
memory T cells (TEM), and central memory T cells (TCM). Both classes are 
CD44High, CD11AHigh, CD69Low and CD25Low. TCM are stereotypically CD45RO
+, 
CD62L+, CCR7+, and CD27High, while TEM
 are CD62L-, CCR7- and CD27Low/Mid 
(Geginat et al., 2003; Hamann et al., 1997; Masopust et al., 2001; Wherry et al., 
2003).  On antigenic stimulation, CTL, TEM and TCM release granules, but the 
granules of TCM are deficient in lytic proteins, and they do not induce lysis (Wolint 
et al., 2004). Thus, while CTL and TEM can immediately induce death of target 
cells, TCM are primarily involved in ongoing immunological surveillance, as they 
can revert to a CTL phenotype on re-exposure to antigen (Oehen and Brduscha-
Riem, 1998; Wherry et al., 2003). The different phenotypes provide tight 
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immunological surveillance – CTL, TEM and TCM can circulate through the 
periphery and respond to current and future infection, while naïve T cells localise 
in the lymphoid tissues awaiting activation (Wherry et al., 2003). In mouse models, 
6-8 days after initial antigen exposure generates an optimal CTL response with 
minimal proliferation (De Boer et al., 2001).  
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Table 1.1 
CD8+ T Cell Surface Phenotype Determines Effector Status. Naive CD8+ 
T cells reside in lymphoid tissues until they are stimulated by APC to divide 
into CTL which rapidly kill target cells. CTL eventually divide to establish 
transient TEM or long-lived TCM populations. TEM also have lytic capabilities. 
Over a period of time TEM also divide into TCM. TCM are unable to immediately 
kill TC and must first divide and return to a CTL phenotype. 
 25 
1.3.2 Death Mediated by CTL 
 
On encounter of a specific target cell (TC), CTL employ two major pathways to 
mediate the removal of such cells. The primary pathway requires the delivery of 
perforin and granzyme-containing lytic granules to the TC. The second is 
dependent on the ligation of Fas receptors (Fas) on the surface of the TC by Fas-
Ligand (FasL) expressed by CTL. Both mechanisms have the net result of 
induction of apoptosis in the TC, and are discussed in more detail in sections 
1.3.4 and 1.3.5 respectively.  
1.3.3 Formation of the Immunological Synapse 
 
Once a T cell recognises an appropriate TC, TCR-conjugation initiates binding 
and segregation of signalling components. This leads to the formation of two 
distinct supramolecular activation clusters (SMAC) at the CTL:TC interface and 
concurrent increases in affinity at the contact site, which becomes known as the 
immunological synapse (IS) (Bunnell et al., 2001; Monks et al., 1998; 
Stinchcombe et al., 2001b; Stinchcombe et al., 2006). Analogous to CD4+ T cell 
immunological synapses, CTL:TC conjugates form a tight central ring enriched in 
TCR, CD3, Lck, and PKC-θ, comprising the central SMAC (cSMAC) (Monks et al., 
1998; Stinchcombe et al., 2001b; Stinchcombe and Griffiths, 2003; Wiedemann et 
al., 2006). The cSMAC is surrounded by a dense ring of LFA-1 and talin, 
comprising the peripheral SMAC (pSMAC) (Grakoui et al., 1999; Monks et al., 
1998; Stinchcombe et al., 2001b; Stinchcombe and Griffiths, 2003). In CD8+ IS, 
some PKC-θ is present in the pSMAC, but the relevance of this is not known. 
More importantly for effective signalling, CD45 is excluded from the cSMAC, 
which allows for optimal TCR/CD3 stimulation (Stinchcombe et al., 2001b), and 
downstream stimulation of signalling events (Janes et al., 1999; Janes et al., 
2000). While formation of an IS is requisite to successful killing by CTL, large 
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enrichment of TCR/CD3 in the cSMAC is not necessary for the initiation of 
apoptosis in the target, suggesting that signalling and lysis are separately 
regulated in CTL (Faroudi et al., 2003; Stinchcombe et al., 2001b; Wiedemann et 
al., 2006). Thus, CTL stimulation can be separated into two stages: first, 
degranulation by CTL to kill TC; and second, activation of immune signalling (i.e., 
IFN-γ production). As the threshold required to induce cytokine production is 
higher than that of degranulation (Faroudi et al., 2003; Wherry et al., 2003), the 
lytic and stimulatory events of CTL activation may be differentially susceptible to 
the effects of MSD. 
1.3.4 Inducing Cell Death via Granule Exocytosis 
 
In conjunction with IS formation, large scale cytoskeletal remodelling occurs in 
CTL (Figure 1.1). Actin microfilaments are excluded from the cSMAC along with 
talin and terminate at the outer edge of the pSMAC (Kuhn and Poenie, 2002; 
Stinchcombe et al., 2001a; Stinchcombe et al., 2001b; Stinchcombe et al., 2006).  
The microtubule network at this point is comprised of two distinct types of 
microtubules – The first type are long sweeping microtubules, of which the plus 
ends contact the plasma membrane within the pSMAC and terminate peripheral 
from the IS; The second type are short straight microtubules that extend from the 
MTOC and terminate within the IS at sites away from the cSMAC (Kuhn and 
Poenie, 2002; Stinchcombe et al., 2006). Simultaneous with pSMAC/cSMAC 
partitioning, the MTOC and associated golgi-apparatus vectorially translocate 
down the long sweeping microtubules to associate with the IS, localising at or 
near the cSMAC (Geiger et al., 1982; Stinchcombe et al., 2001b). Thus, by the 
time the MTOC associates with the IS, actin filaments and microtubule plus-ends 
have been cleared from the site of lytic granule delivery (Kuhn and Poenie, 2002; 
Stinchcombe et al., 2006). 
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After MTOC polarisation, preformed lytic granules stored in the cell periphery 
traffic down microtubules and cluster around the MTOC (Stinchcombe et al., 
2001b; Stinchcombe et al., 2006). Lytic granule mediated cytolysis can take place 
in the absence of plus-end movements of lytic granules, suggesting a unique 
exocytosis mechanism, likely involving dyneins, in lytic granule delivery (Kuhn and 
Poenie, 2002; Stinchcombe et al., 2006). During killing, the CTL MTOC 
dynamically oscillates across the IS in single CTL:TC conjugates, at times 
contacting the plasma membrane (Kuhn and Poenie, 2002). Lytic granules detach 
from the microtubule network to be delivered to the TC via the golgi apparatus 
(Bossi and Griffiths, 2005; Stinchcombe et al., 2001a). As lytic granules dissociate 
from the microtubule network they release their contents in a static secretory 
domain between the cSMAC and pSMAC, defined visually by a pre-formed 
invagination in the TC membrane (Stinchcombe et al., 2001b; Stinchcombe and 
Griffiths, 2003). The high concentration of lytic proteins found within lytic granules, 
including a range of granzymes (primarily A,B,C) and perforin (cytolysin), induces 
apoptosis in the TC (Konigsberg and Podack, 1986; Macdermott et al., 1986; 
Munger et al., 1986; Peters et al., 1991; Podack and Dennert, 1983; Podack and 
Konigsberg, 1984). After granule delivery, CTL can dissociate from TC and 
recirculate to kill multiple TC in a similar manner (Chuang, 1994; Chuang et al., 
1994). The whole process occurs very rapidly, with the time from initial antigen 
encounter to measurable apoptosis generally occurring in less than 20 minutes in 
vitro and in vivo (Mempel et al., 2006; Stinchcombe et al., 2001b). 
 
The importance of degranulation is demonstrated in both in vitro and in vivo 
processes. In vitro, CTL deficient in perforin, one of the key lytic granule proteins, 
are severely impaired in lytic capacity (Kagi et al., 1994; Lowin et al., 1994). In 
vivo, Tumour-infiltrating lymphocytes (TIL) are rendered unable to polarise and 
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deliver granules to TC and are accordingly unable to elicit killing (Radoja et al., 
2001); and TREG greatly impair TC killing by CTL by inhibiting granule release 
(Mempel et al., 2006). However, the most striking example of the involvement of 
degranulation in CTL-mediated cytolysis is demonstrated by CTL generated from 
Ashen mice. CTL from these mice lack the small Ras-like GTPase Rab27a, which 
is required for lytic granules to dock and release their contents at the CTL:TC 
interface (Stinchcombe et al., 2001a). Because of this deficiency, CTL from Ashen 
mice are rendered incapable of killing certain types of TC (Stinchcombe et al., 
2001a). 
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Involvement of the microtubule network in lytic granule delivery. (1) When a 
CTL (whole cell) recognises a TC (shown in part) an IS is formed and the MTOC 
(red) relocalises and associates with the CTL:TC interface, known as the 
immunological synapse (2). (3) Lytic granules (blue) traffic down microtubules (4) 
and cluster around the MTOC (5) for delivery to and induction of apoptosis in the 
TC (6). 
Figure 1.1 
1 2 3 
4 5 
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1.3.5 Fas-Ligand Mediated Cell-Death 
 
The second pathway CTL employ to kill TC involves the ligation of Fas on the TC 
by Fas Ligand (FasL) expressed on the surface of the CTL. FasL exists in two 
forms: As either membrane bound FasL or soluble FasL (sFasL). While in humans 
sFasL can induce diapedesis and has cytolytic activity (Seino et al., 1998; Tanaka 
et al., 1995), murine sFasL is minimally active, operating solely as a competitive 
inhibitor for Fas binding (Hohlbaum et al., 2000; Tanaka et al., 1995).  
 
The intracellular domain of Fas shares sequence homology with the apoptosis-
inducing death domain of TNF-RI (Itoh and Nagata, 1993; Nagata and Golstein, 
1995). When expressed in non-haematopoietic cells, FasL is constitutively 
expressed and limits autoimmunity at immunologically priviledged sites (Bossi and 
Griffiths, 1999; Bossi et al., 2000). In contrast, FasL is only expressed by CTL on 
CD3/TCR activation (Vignaux et al., 1995). FasL can compensate for deficiencies 
in the perforin/granzyme (i.e., lytic granule) pathway (Kagi et al., 1995; Lowin et 
al., 1994), and is essential in the clearance of some viral infections (Abougergi et 
al., 2005). While only expressed in CTL on activation, control of FasL expression 
in CTL is biphasic. Pre-formed FasL is stored in lytic granules and on CTL 
activation is delivered to the surface in lytic granules (Blott et al., 2001; Bossi and 
Griffiths, 1999; Bossi et al., 2000). FasL synthesised thereafter, however, is 
expressed directly on the CTL surface (He and Ostergaard, 2007). This second 
phase of FasL expression bypasses the granule component and does not require 
the microtubule network (He and Ostergaard, 2007). Thus, to be functional, 
murine FasL needs to be present on the plasma membrane of CTL, but can be 
expressed in the absence of degranulation and compensate for deficiencies in the 
perforin/granzyme pathway (He and Ostergaard, 2007; Lowin et al., 1994). 
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1.3.6 The Known Effects of Microtubule Actives on Lymphocyte 
Function 
 
Early work investigating the role of the microtubule network in CTL function 
primarily employed DSD. While actin microfilaments, and not microtubules, are 
involved in initial TC recognition (Bunnell et al., 2001; Plaut et al., 1973), 
microtubules are involved in stabilising the IS (Bunnell et al., 2001). DSD also 
reduce the TCR turnover rate at the IS, which may affect signalling events (Das et 
al., 2004). Most importantly, destroying the microtubule network prevents lethal hit 
delivery and inhibits cytolysis in vitro (Plaut et al., 1973). The inhibitory effect DSD 
have occurs primarily because they block CTL polarisation by preventing 
relocalisation of the MTOC adjacent to the TC, precluding all the downstream 
events involved in killing (Geiger et al., 1982; Kupfer and Dennert, 1984; Kupfer et 
al., 1985).  
 
Studies into the effects of MSD on lymphocytes have concentrated on the use of 
paclitaxel. Paclitaxel induces G2/M-phase block in proliferating lymphocytes in 
vitro (Brown et al., 1985). Paclitaxel also inhibits allogeneic activation of cells in 
the mixed lymphocyte reaction (MLR), but only when responding cells, not 
stimulators, are treated with paclitaxel (Roy et al., 1988). In human NK T cells, 
paclitaxel inhibits TC death without killing the effector cells (Markasz et al., 2007). 
Two separate studies have analysed paclitaxel in human CTL, both showing that 
the ability of CTL to kill multiple targets is inhibited at low micromolar 
concentrations in vitro (Chuang et al., 1994; Markasz et al., 2008). However, in 
the murine system micromolar concentrations of paclitaxel induce microtubule 
bundling in interphase CTL, but do not inhibit in vitro cytolysis by CTL (Brown et 
al., 1985; Knox et al., 1993). Further, low-dose paclitaxel can partially abrogate 
the inhibitory effects of DSD on killing (Kupfer et al., 1983; Wolberg et al., 1984).  
 32 
 
The immunological effects of peloruside on lymphocytes are less widely explored. 
Peloruside is known to inhibit IL-2 and IFN-γ production by killing splenocytes 
stimulated with T cell mitogens, as well as in the MLR (Crume et al., 2007; Hood 
et al., 2001; Miller et al., 2004). Aside from this, little is known about the effects 
the compound has on immediate processes, such as CTL-mediated cytolysis. 
 
In contrast to human CTL, studies into the effects of paclitaxel did not 
demonstrate effects on murine CTL function (Knox et al., 1993). However, the 
initial study by Knox et al. only investigated the effects at high CTL:TC ratios 
(Knox et al., 1993). Due to the known importance of dynamic instability in other 
cell transport mechanisms and the involvement of the cytoskeleton in lytic granule 
delivery, it is possible that under more limited circumstances such as at lower 
CTL:TC ratios, or in an in vivo setting, effects of MSD may become more 
apparent. Further, because the mechanisms of microtubule stabilisation by 
paclitaxel and peloruside differ, these two agents may differentially affect 
degranulation and cell death. Thus, there is reason to believe paclitaxel and 
peloruside may differently or similarly affect CTL function in vitro and MSD may 
alter killing processes in vivo. Determining how these agents affect CTL function 
will identify immediate effects of MSD therapy on the immune system and better 
clarify the involvement of microtubules in the normal immune response.
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2 Methods 
2.1 Mice 
BALB/c mice were from breeders at VUW. C57BL/6 mice were purchased from 
the Otago School of Medicine Biomedical Research Unit, Wellington, New 
Zealand. OT-I and OT-I/ptp-rca mice were kindly provided by Prof. Franca 
Ronchese at the Malaghan Institute of Medical Research (MIMR). OT-I mice 
possess an enriched population of T cells expressing Vα2/Vβ5.1/5.2-TCR specific for 
the SIINFEKL peptide of OVA (Hogquist et al., 1994). T cells from OT-I/ptp-rca 
mice are SIINFEKL-peptide specific and CD45.1+/CD45.2+, whereas C57BL/6 T 
cells only express CD45.2. Thus, populations of OT-I/ptp-rca T cells can be 
tracked in C57BL/6 mice by measuring CD45.1 expression. Mice used for in vivo 
work were housed in a 12-hour light/dark cycle and experiments started early in 
the light cycle. Mice were euthanized by CO2 asphyxiation and tissues removed 
by blunt dissection with forceps and scissors sterilised in 100% ethanol. All mouse 
work was done in accordance with the guidelines of the Victoria University of 
Wellington Animal Ethics Committee.  
2.2 Reagents 
 
Paclitaxel purified from Taxus yannanensis, colchicine and LPS (from E. coli) 
were purchased from Sigma Chemical Company (St. Louis, MO, USA). Taxol® 
(Taxol; in Cremophor; Bristol Myers Squibb, New York City, NY, USA) was 
purchased from Capital Coast Chemists (Wellington, New Zealand). Cremophor 
EL® was purchased from Sigma-Aldrich-Fluka (Taufkirchen, Germany). 
Peloruside was provided by Dr. Peter Northcote (Victoria University of Wellington, 
School of Chemical and Physical Sciences). Paclitaxel and peloruside stocks 
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were dissolved in ethanol at 1 mM and stored at -80°C. Colchicine was 
dissolved in ethanol at 1 mM and stored at room temperature protected from light. 
2.3 Cell Culture 
2.3.1 BMMØ Culture 
BMMØ culture has been described previously (Crume et al., 2007). Femurs and 
tibias were excised from euthanised C57BL/6 or BALB/c mice and 5 mL 
Dulbecco‟s phosphate buffered saline (dPBS; Invitrogen, Auckland, New Zealand) 
was flushed through each bone. The elute was collected into a 50 mL polystyrene 
tube (Falcon, Franklin Lakes, NJ, USA). Clumps of marrow were disrupted and 
red blood cells were lysed with 2 mL Red Blood Cell Lysing Buffer (Sigma). Cells 
were seeded in 10 or 30 mL volumes in T-25 or T-75 tissue culture flasks 
(Greiner, Monroe, NC, USA) respectively at 4x105-1x106/mL in complete T cell 
medium (CTCM; see Appendix A) overnight. The following day GM-CSF and IL-3 
(from supernatants from the GM-KLON and WEHI-3 cell lines respectively) were 
added and the non-adherent population cultured for a further 7-9 days. Cells were 
fed on day 4 or day 5 with the original volume of CTCM and cytokines. After a 
total of 8-10 days culture the non-adherent fraction was removed, the plates 
washed briefly with dPBS and vigorously blasted with ice-cold dPBS to remove 
the adherent population. These cells were deemed „BMMØ‟. BMMØ were washed 
once in handling medium (Appendix A) prior to use. In all experiments BMMØ 
were checked visually for large, adherent granular cells.  Cultures were typically 
80-95% CD11b+, F4/80high, I-Ab+, GR-1-PElow/mid as determined by flow cytometry. 
2.3.2 LPS Stimulation of BMMØ 
 
Following culture, 5x104 BMMØ were seeded at 2.5x105/mL in 96-well flat-
bottomed plates (Falcon). Unless otherwise stated, BMMØ were stimulated 
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overnight with 40 U/mL IFN-γ. After 12-18 hours, 100 µL of the supernatant was 
replaced with CTCM or CTCM+LPS with or without paclitaxel or ethanol (as 
vehicle control). Final concentrations are stated in figures. For TNF-α analysis, 
100 µL supernatant from each well was removed and frozen at -20°C for TNF-α 
ELISA. The cells were incubated for a final total of 72 hours and subjected to the 
Greiss Reaction and the MTT Assay (described below). 
2.3.3 BMDC Culture 
BMDC were cultured from C57BL/6 mice as previously described (Yang et al., 
2006). Femurs and tibias were flushed with 5mL Iscove‟s modified Dulbecco‟s 
medium (IMDM; Invitrogen), the cells washed once in IMDM and cultured in 
cIMDM (Appendix A) in 5 mL aliquots at 4x105/mL in 6-well tissue culture plates 
(Invitrogen) in the presence of 20 ng/mL recombinant murine GM-CSF and 20 
ng/mL recombinant murine IL-4. On days 3 and 5 of culture 2 mL of the 
supernatant was carefully replaced with 2 mL cIMDM containing the original 
volume of cytokines. On day 6 BMDC were matured with 100 ng/mL LPS for 16-
20 hours before use in further experiments. The majority of LPS-matured BMDC 
were typically CD11bhigh, I-Ab+ and CD11cMid. Cultures were also checked visually 
for typical BMDC morphology (medium to large cells extending whispy dendrites). 
2.3.4 CTL Culture 
For in vitro CTL culture, OT-I or OT-I-ptprca mice were euthanized and inguinal, 
brachial, axillary, cervical and mesenteric lymph nodes (LN) were excised. Cells 
were separated by disrupting the LN capsules and passing through 70 µm pore 
size strainers (Falcon). LN cells were washed once in IMDM and combined with 
LPS-matured BMDC that had been incubated with 0.1 µM SIINFEKL peptide (JPT 
Peptide Technologies GmbH, Berlin, Germany) for 4 hours. Cells were incubated 
at final concentrations of 1.25x104/mL (BMDC) and 1x105 /mL (LN cells) in 5 mL 
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aliquots of cIMDM in 6-well plates. After 4 days the non-adherent fraction was 
removed, washed once and cultured at 2.5x105/mL in cIMDM containing 100U/mL 
recombinant human IL-2 in T-75 tissue culture flasks. IL-2 was replaced after 24 
hours of culture and CTL were used the following day. CTL were generally >99% 
Vα2/Vβ5.1/5.2-TCR-specific, of which 98-99% were CD8
+, 98% CD44high and >90% 
CD62Llow as determined by flow cytometry. Visually, CTL were larger and less 
spherical than naïve T cells. 
2.3.5 EL-4 Cell line maintenance 
Seeder stocks of the murine T-cell hybridoma/thymoma EL-4 were grown from a 
stock from the MIMR and stored in Freezing Medium (Appendix A) in liquid 
nitrogen. Cells were maintained in T-25 and T-75 tissue culture flasks at a density 
of 2x105-2x106/mL for a maximum of 20 passages in cIMDM.  
2.4 MTT Assay 
The MTT assay was used to determine metabolic activity of cell cultures as 
described previously (Crume et al., 2007). In experiments with BMMØ, after the 
removal of supernatant for the Greiss Reaction, 50 µL CTCM and 20 µL sterile 
filtered 5 mg/mL (3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide) 
(MTT; Sigma) in dPBS was added to each well. For JAM assay controls (refer to 
page 38), after a 4 hour pre-treatment with 1 µM paclitaxel, 1 µM peloruside or 
0.1% ethanol as vehicle control, CTL (1x105/well) were washed once and 
incubated in 100 µL fresh medium in 96-well flat bottomed plates for 4 hours. 
When JAM plates were harvested, 20 µL MTT was added to each well of the MTT 
plate. For degranulation assay controls, after pre-treatment CTL were overlayed 
with 100 µL cIMDM and incubated until the end of the degranulation assay (4 or 6 
hours). While degranulation plates were being stained MTT plates were spun for 
60 seconds at 50g to settle the cells to the bottom of wells, 100 µL supernatant 
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carefully removed and 20 µL MTT was added to each well. In all cases plates 
were incubated for 2-2.5 hours with MTT and the reaction was stopped with 100 
µL 10% weight/volume sodium dodecyl sulfate (Sigma) in 0.01N HCl. Plates were 
incubated overnight to allow the crystals to solubilise and read on a Versamax 
plate reader (Molecular Devices; Sunnyvale, CA, USA) at 570 nanometers the 
following day.  
2.5 ELISA 
Enzyme-linked Immunosorbant Assays (ELISA) were run as per the 
manufacturer‟s recommendations and unless stated ELISA reagents were from 
BD Bioscience. Washes were in 0.05% Tween-20 (Sigma) in phosphate buffered 
saline (PBS; Appendix A). Capture antibodies used were Rat-anti-mouse-TNF-α 
or Rat-anti-mouse-IFN-γ. Capture was done in 96-well ELISA plates (Greiner) 
overnight at 4°C by diluting the capture antibody in sodium phosphate buffer 
pH=6.0 for TNF-α and pH=9.0 for IFN-γ. All subsequent steps were done at room 
temperature. Plates were blocked with blocking buffer (5% foetal calf serum (FCS; 
Invitrogen) in PBS) for 2 hours. After four washes; standards and samples (either 
neat or diluted in blocking buffer) were added to wells for 2 hours. Plates were 
washed four more times and incubated with a biotinylated detection antibody for 
TNF-α or IFN-γ; incubated for 1 hour then washed six more times. Plates were 
then incubated with streptavidin-horse radish peroxidase for 1 hour and washed 8 
times. TMB reagents “A” and “B” were combined and added to each well. After 
sufficient colour development the reaction was stopped by the addition of 100 µL 
0.18 M sulfuric acid. Plates were read at 450 nanometers and cytokine 
concentrations were calculated by comparing sample absorbances to the 
standards. 
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2.6 Greiss Reaction 
The Greiss Reaction was used to measure NO production as described previously 
(Crume et al., 2007). NO gas is unstable and breaks down rapidly to form nitrite 
(NO2
-) and nitrate which accumulate in culture (Stuehr and Marletta, 1985). By 
measuring NO2
-, the Greiss reaction provides a relative measure of NO 
production. 72 hours after BMMØ were activated with LPS 50 µL of culture 
supernatants were removed to wells of a 96-well flat-bottomed ELISA plate. 
Greiss reagents A and B (Appendix A) were combined in equal volumes and 50 
µL added to each sample well; each plate contained a row of titrated standards. 
Plates were read at 570 nanometers in a plate reader and NO production 
calculated by comparing to the standard curve. 
2.7 JAM assay 
The Just Another Method (JAM) assay has been described previously (Matzinger, 
1991; Usharauli et al., 2006). When radioactively-labelled TC are induced to 
apoptose by effector cells, TC DNA is cleaved to a size that passes through a 
filtermat while intact DNA is trapped (Matzinger, 1991). This results in a reduction 
in radioactivity in wells with specific killing. OT-I CTL were used as effector cells 
and EL-4 cells were TC. TC split the day before were incubated overnight in 6-well 
plates in cIMDM containing 2 µCi/mL [methyl-3H]Thymidine (GE Healthcare, 
Auckland, New Zealand). The following day TC were washed twice and incubated 
for 60-90 minutes at 5x104/mL in cIMDM with (Ag+) or without (Ag-) 10 ng/mL 
SIINFEKL peptide. 5x103 Ag+ TC or 5x103 Ag- TC were combined with CTL 
titrated out in half-logs to give final CTL:TC ratios of 50:1-0.4:1 in a volume of 200 
µL in 96-well round bottomed plates. In some assays CTL were pre-treated for 4 
hours at 1x106/mL with 1 µM paclitaxel, 1 µM peloruside or 0.1% ethanol (as 
vehicle control) in 5 mL polystyrene tubes (Falcon). Following pre-treatment CTL 
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were washed and resuspended to the specified ratios in drug-free medium. 
After combining CTL and TC, plates were spun for 60 seconds at 50g to promote 
CTL:TC conjugation. Plates were incubated at 37°C for 4-4.5 hours and 
immediately harvested onto 96-well plate glass fibre filters (Wallac, Perkin Elmer, 
Boston, USA) in an automated Mach-III-FM cell harvester (Tomtec, Hamden, CT, 
USA). Radioactivity was measured in scintillations per minute (cpm) determined 
by liquid scintillation counting in Betaplate Scint (Wallac). Specific Lysis was 
calculated as: Specific Lysis = 100 - % Specific Survival; % Specific Survival was 
normalised to Ag+ TC without effectors as: % Specific Survival = (x/µy) * 100; 
Where x = cpm of wells with CTL and µy = mean cpm wells without effectors. 
Spontaneous lysis was controlled for by harvesting a TC-only plate at the start 
and comparing cpm to control wells at the end of the assay. Spontaneous lysis 
was generally 5-30%.  
2.8 Degranulation assay 
CTL (1x105/well) were pre-treated for 4 hours with peloruside, paclitaxel, 
colchicine or ethanol in 100 µL at concentrations specified in the text. At the start 
of the assay, wells were topped up with an equal volume of media containing 
CD107a-Fitc (final concentration 2.5 µg/mL) or non-specific IgG2α-Fitc antibody 
with or without SIINFEKL peptide to a final concentration of 25 nM, thus halving 
the drug concentration for the remainder of the assay. When a pre-treatment step 
was not used the final concentration of colchicine relates to the final 200 µL 
volume. After 2, 4 or 6 hours as stated in the text, plates were spun down, 100 µL 
of the supernatant was removed from each well and frozen at -20°C for IFN-γ 
ELISA. The cells were then stained for CD8 and subjected to flow cytometry 
procedures. Live gates were set with control antibodies and IFN-γ production was 
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determined by combining results from all peptide-treated wells. The antibody 
used did not affect IFN-γ production at any timepoint (data not shown). 
2.9 Confocal Microscopy 
2.9.1 Coverslip preparation for CTL 
Thirteen millimetre round glass coverslips were stored in 70% ethanol and on the 
day before use sterilised by flaming. When dry, coverslips were put into 6-well 
plates, and coated with 200 µL 10 µg/mL poly-D/L-lysine hydrobromide (PDL; 
Sigma). PDL was removed, coverslips were washed twice in double-distilled 
water, and dried under sterile conditions. Coverslips were stored under sterile 
conditions at 4°C until use.  
2.9.2 Staining of CTL 
CTL were incubated with drug as specified in figure legends. After 4 hours, 1x105 
cells (100 µL) were aliquoted onto coverslips and allowed to adhere for 30 
minutes. Coverslips were transferred directly into ice-cold 1:1 Acetone:Methanol 
and fixed for 7 minutes at room temperature. Coverslips were washed twice for 5 
minutes in PBS and permeabilised in permeabilisation buffer (0.25% Triton-X 100 
(Sigma) in 1% bovine serum albumin (Invitrogen) in PBS) for 30 minutes. 
Coverslips were then incubated overnight at 4°C with 30 µL 1 µg/mL polyclonal 
rabbit anti-alpha-tubulin-IgG (Abcam; Sapphire Biosciences, Redfern, Australia) in 
permeabilisiation buffer. The following day coverslips were washed three times for 
5 minutes in PBS and incubated for 1 hour at room temperature in the dark with 
30 µL 1 µg/mL Alexafluor-488 goat-anti-rabbit-IgG (Invitrogen). Coverslips were 
washed three times for 5 minutes in PBS, overlayed with 10 µL Prolong Gold® 
antifade with DAPI (Invitrogen) and sealed with nail polish. Microtubules and 
nuclei were visualised with a 60 x oil immersion objective lens using an Olympus 
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FluoView FV1000 confocal laser scanning biological microscope (inverted 
model IX81) using sequential frame acquisition. Images were acquired using 
Olympus FV10-ASW software. 
2.10  In Vivo Assay of Cell Death 
2.10.1 Immunisation 
 
The in vivo VITAL assay was adapted from Hermans et al. (Hermans et al., 2004). 
BMDC were incubated for 2 hours at 1x106/mL in cIMDM with or without 1 µM 
SIINFEKL peptide, washed once and resuspended in IMDM at 1x106/mL. 1x105 
Ag+-BMDC or 1x105 Ag--BMDC were injected subcutaneously into the right flank 
of C57BL/6 mice for immunised and unimmunised groups respectively. For 
adoptive transfer experiments, 1x106 LN cells from naïve OT-I-ptprca mice were 
injected into congenic C57BL/6 recipients via the lateral tail vein 1 day prior to 
immunisation. 
2.10.2 CFSE & CTO labelling of splenocytes 
 
Splenocytes from naïve syngenic C57BL/6 mice were harvested and flushed 
through 70 µm pore size strainers. Red blood cells were lysed and cells 
resuspended at 1x106/mL in cIMDM and incubated for at least 60 minutes with or 
without 1 µM SIINFEKL-peptide for Ag+ TC and Ag- TC respectively. Ag- TC were 
washed once in IMDM and incubated in cIMDM with 10 µM Cell Tracker Orange® 
(CTO; Invitrogen) for 15 minutes at 2x107/mL, and then incubated in medium 
alone for 15 minutes. Ag+ TC were washed in dPBS and incubated at 2x107/mL in 
dPBS with 200 nM 5,6-carboxyfluorescein succinimidyl ester (CFSE; Sigma) for 8 
minutes at room temperature. CFSE labelling was quenched with 2.5 volumes of 
FCS. Both Ag+ TC and Ag- TC were washed twice in IMDM, resuspended at 
4x107/mL in IMDM and combined for adoptive transfer. 
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2.10.3 The in vivo VITAL assay 
 
 One week after immunisation mice were given a single intraperitoneal dose of 20 
mg/kg or 30 mg/kg Taxol or an equivalent dose Cremophor EL® (as vehicle 
control). Groups were sib- and weight matched; drug doses were based on 
average weight to the nearest 2.5g in a given experiment. The drug dose was 
based on the work of Innocenti et al., suggesting that intraperitoneal 
administration of 18-36 mg/kg Taxol results in plasma concentrations of >1 µM for 
the first few hours after injection (Innocenti et al., 1995), and thus was likely to 
provide comparable concentrations to those used in in vitro CTL work (chapter 4).   
 
Approximately 2 hours after drug administration 200 µL (8x106) TC were injected 
into each mouse via the lateral tail vein. The TC contained an equal mix of CFSE-
labelled SIINFEKL+ (Ag+) TC and CTO-labelled control (Ag-) TC prepared as 
outlined in the previous section. After 8 or 10 hours as specified in the text mice 
were euthanized and splenocytes stained for CD8 or CD8+CD45.1 and subjected 
to flow cytometric analysis. Total CD8+ or CD8+/CD45.1+ T cell number was 
calculated by multiplying the proportion of CD8+ or CD8+/CD45.1+ splenocytes 
determined from flow cytometry data by the total number of splenocytes 
determined by the Trypan Blue Exclusion test. One control mouse in adoptive 
transfer experiments was excluded as its CD45.1+/CD8+ T cell numbers and killing 
profile matched that of unimmunised mice. Mice with <400 events in the Ag- gate 
were also excluded from analyses. Specific Lysis was determined by subtracting 
Specific Survival from 100%. Specific Survival was calculated as the proportion of 
Ag+/Ag- splenocytes in immunised mice normalised to unimmunised mice with the 
same drug treatment multiplied by 100. The final calculation is as follows: 
 
SLA=100-(Ag
+
A/Ag
-
A)/(µDU)*100 
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Where SLA= Specific Lysis in mouse A;  
µDU= mean Ag
+/Ag- of unimmunised mice receiving the same drug treatment. 
2.11  General Flow Cytometry  
Staining for flow cytometry was done in eppendorfs or 96-well round bottomed 
plates (Falcon). Samples were washed twice in FACS buffer (Appendix A) and Fc-
Receptors blocked with 1 µg/mL 24G2 antibody for 5 minutes prior to the addition 
of primary antibodies. Samples were incubated with primary antibodies or relevant 
isotype controls at 4°C for 30 minutes (Appendix B contains sources of all 
antibodies). Samples were washed twice in FACS buffer and resuspended for flow 
cytometry. When a secondary antibody (Streptavidin-Cyc) was used, cells were 
incubated with the antibody at 4°C for 10 minutes, washed twice and resuspended 
for flow cytometry. In some assays samples were stored overnight at 4°C prior to 
collection. Samples were collected with a FACSScan, FACScalibur or FACSort 
flow cytometer mounted with Cellquestpro (Becton Dickinson, Franklin Lakes, NJ, 
USA). Background fluorescence was set with isotype controls, and compensation 
was done with single antibody stains. FLOWJO 8.8.4 (Tree Star, Ashland, OR, 
USA) or Cellquestpro were used to graph data. 
 
2.12  Trypan Blue Exclusion Test 
 
Viable cell number was determined by mixing a known volume of cells with 0.4% 
trypan blue (Sigma). 2 to 4 fields were counted and multiplied by the dilution factor 
field volume, and total volume to determine overall cell number. In in vivo assays, 
total numbers of CD8+ and CD8+/CD45.1+ CTL were back-calculated after 
determining relative proportions of total live cells. 
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2.13  Statistics 
Data were graphed in Graphpadprism 4.0 (Graphpad Software Inc., San Diego, 
CA, USA). Student‟s t-test, One-way ANOVA with Bonferroni correction, Two-way 
ANOVA with Bonferroni correction and linear regression analysis were performed 
in Graphpadprism. Student‟s t-test was used in adoptive transfer experiments due 
to low group numbers. In JAM assays, after calculating mean % specific lysis, 
group means at different CTL:TC ratios were ranked and compared using 
Friedman‟s mean rank sum test against a table of Chi(Χ)-square statistics by the 
formula: 
 
Χ2=12*S/(n*g*(g+1)) 
Where n=number of means in samples; g=number of drug treatments; and  
S=(RanksumA)
2+(RanksumB)
2+(RanksumC)
2-(Sumranksum)2 
Where RanksumA=The total of the ranked means for drug A; and 
Sumranksum=The sum of all the ranked sums for all the groups 
 
Unless otherwise stated, bar graphs show group mean plus standard error of the 
mean (SEM). 
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3 Interactions of Lipopolysaccharide and Paclitaxel on 
Proinflammatory Processes in Macrophages 
3.1 Introduction 
 
Paclitaxel stimulates proinflammatory pathways, especially those leading to TNF-
α and NO production in BMMØ, by binding to and activating TLR-4 in a manner 
similar to LPS (Bogdan and Ding, 1992; Byrd-Leifer C.A. et al., 2001; Crume et 
al., 2007; Ding et al., 1990b; Kawasaki et al., 2000; Kirikae et al., 1996; Manthey 
et al., 1994; Manthey et al., 1993). Figure 3.1A illustrates the ability of paclitaxel to 
induce TNF-α production by IFN-γ-primed BMMØ. In contrast, when IFN-γ-primed 
BMMØ are activated with LPS, production is dose-dependently inhibited by both 
paclitaxel (Figure 3.1B; (Crume et al., 2007)) and peloruside (Crume et al., 2007). 
To better understand the contradictory effects of paclitaxel on TNF-α production, 
we investigated the relationship between LPS concentration and paclitaxel-
mediated inhibition to determine the conditions that induce the optimal inhibitory 
response.  
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3.2 Results 
3.2.1 Paclitaxel inhibits IFN-γ-primed BMMØ responses to LPS in a 
broad time window 
 
The first set of experiments aimed to determine if IFN-γ priming was essential to 
the observed inhibitory effects of paclitaxel on LPS-stimulated BMMØ. Previous 
studies have shown that BMMØ primed with IFN-γ are far more responsive to LPS 
than unprimed MØ (Gifford and Lohmann-Matthes, 1987; Yamamoto et al., 1994). 
As shown in Figure 3.2, when primed, BMMØ respond strongly to lower levels of 
LPS than unprimed MØ. IFN-γ renders cells increasingly sensitive to LPS and this 
augmentation reaches its maximum between 8 and 12 hours (Chung and 
Benveniste, 1990; Ma et al., 1996). Thus, we wished to determine if the inhibition 
of LPS-stimulated TNF-α production by MSD was due to a delay or defect in the 
IFN-γ priming response. By priming BMMØ for various times after the previous 
period of 12 hours we saw no shift in inhibition by paclitaxel (Figure 3.3A&B). This 
suggests that paclitaxel does not defer augmentation by IFN-γ and that the 
interaction of paclitaxel and IFN-γ is consistent after 12 hours priming.  
3.2.2 Altered Production Kinetics do not Explain Inhibition of TNF-
α production 
 
One possible explanation for paclitaxel-mediated inhibition of TNF-α production by 
LPS-stimulated BMMØ is that the kinetics of TNF-α production are altered. TNF-α 
feeds back on TNF-RI and TNF-RII expressed by MØ which can induce NO and 
further augment TNF-α production (Miller et al., 1996; Vila-del Sol et al., 2006). 
Moreover, bioactive TNF-α bound by TNF receptors can be taken up and 
removed from culture by MØ (Fujihara et al., 1994; Virca et al., 1989).  Thus, we 
postulated MSD may lead to an early peak in extracellular TNF-α and subsequent 
reduction in detectable levels by 8 hours. However, while TNF-α production by 
LPS-stimulated, IFN-γ-primed BMMØ increases between 2 and 8 hours (Figure 
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3.4A), the addition of paclitaxel does not alter the time of peak production 
(Figure 3.4B). Instead, paclitaxel significantly inhibited production of TNF-α at 6 
and 8 hours. This finding suggests that paclitaxel does not alter the kinetics of 
LPS-induced TNF-α production by promoting early enhanced production.  
3.2.3 Paclitaxel inhibits TNF-α and NO production in a manner 
dependent on LPS-responsiveness 
 
Work by other groups suggests that TNF-α production can decrease above an 
optimal concentration of LPS (Chung and Benveniste, 1990; Kastenbauer and 
Ziegler-Heitbrock, 1999; Kikkawa et al., 1998; Takasuka et al., 1991). Further, 
pre-treatment of MØ with low-dose LPS can exacerbate this decrease, inhibiting 
and even ablating TNF-α production on restimulation with LPS (Hirohashi and 
Morrison, 1996; Nakano et al., 1999; Shnyra et al., 1998; Zhang and Morrison, 
1993a, b). Thus, we sought to determine if there was a concentration-dependent 
interaction for TNF-α with LPS, and whether altering this LPS concentration 
affected the inhibition seen by paclitaxel. BMMØ primed with IFN-γ for 18 hours 
were treated with 10 µM paclitaxel, an equivalent concentration of ethanol 
(vehicle) or medium alone and activated with concentrations of LPS ranging from 
0.5 ng/mL to 128 ng/mL for 8 hours. As shown in Figure 3.5A, TNF-α produced by 
LPS-stimulated BMMØ peaked at 4 ng/mL and above this LPS concentration, 
TNF-α production decreased to a basal level. As shown by other groups, it is also 
observed that the presence of ethanol affected TNF-α production on LPS 
activation (Feng et al., 2002; Fernandez-Lizarbe et al., 2008; Kolls et al., 1995; 
Shi et al., 2002; Stoltz et al., 2000; Xie et al., 1995). While inhibition by ethanol 
was not always this pronounced (c.f. Figure 3.3A), peak TNF-α production by 
LPS-stimulated BMMØ occurred at the same concentration as medium alone (4 
ng/mL), and also decreased to basal levels above 4 ng/mL. Paclitaxel inhibited 
TNF-α production compared with vehicle control at concentrations of LPS where 
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TNF-α production was highest (i.e., 1-8 ng/mL). Above 8 ng/mL LPS and below 
1 ng/mL, no inhibition of TNF-α could be seen by paclitaxel against vehicle or 
medium alone. From these studies we conclude that the greatest level of inhibition 
of TNF-α production by paclitaxel is found at optimal LPS responsive levels. 
 
Additionally, because TNF-α production peaked similarly (<16 ng/mL LPS) in all 
three conditions, this experiment supports our previous finding that paclitaxel does 
not shift LPS-responsivity of BMMØ. That is, paclitaxel did not alter TNF-α 
production such that peak production occurred at a lower or a higher 
concentration of LPS, but paclitaxel generally depressed TNF-α production at 
optimal LPS responsive levels. Therefore we conclude that a shift in peak LPS 
responsiveness by paclitaxel does not explain inhibition by MSD.  
 
3.2.4 NO Production is inhibited by Paclitaxel at LPS 
Concentrations above which TNF-α Inhibition is seen 
 
iNOS is the main enzyme responsible for the production of inducible NO and it is 
expressed by LPS-activated IFN-γ-primed BMMØ (Santos et al., 2006). IFN-γ also 
operates in synergy with TNF-α to produce large amounts of NO (Geller et al., 
1993; Vila-del Sol et al., 2006). It has therefore been suggested that inhibiting 
TNF-α production may cause a subsequent decrease in NO production by LPS-
stimulated BMMØ (Crume et al., 2007).  
 
After removal of a portion of the supernatant at 8 hours to measure TNF-α, cells 
were incubated for a further 64 hours and assayed for NO production (Figure 
3.5B). Unlike TNF-α, NO breaks down to form nitrate and NO2
- which cannot be 
removed by BMMØ and accumulate over the course of the assay (Stuehr and 
Marletta, 1985; Stuehr and Marletta, 1987). Thus by measuring NO2
- the total 
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amount of NO produced can be determined at later times than TNF-α. In the 
presence of 10 µM paclitaxel, IFN-γ-primed BMMØ NO production was 
significantly inhibited at 4 ng/mL LPS and above (p<0.05, Two-way ANOVA with 
Bonferroni correction). By comparing TNF-α and NO production from these cells 
(Figure 3.5A & Figure 3.5B) there was overlap in inhibition where control TNF-α 
production was optimal, but at concentrations above 16 ng/mL, where TNF-α 
production reduced to basal levels, NO production became increasingly inhibited. 
When assessed together these findings may suggest that NO production is 
inhibited by paclitaxel in a manner independent of generation by TNF-α. 
3.2.5 Myeloid-derived cells show increased metabolism in the 
presence of paclitaxel 
 
One previously noted phenomenon is the specific increase in metabolic activity of 
BMMØ treated with high dose (1-10 µM) paclitaxel (Crume et al., 2007). Figure 
3.6A shows a 10 µM dose of paclitaxel pronouncedly increases metabolic activity 
of BMMØ (p<0.01 by Student‟s t-test; paclitaxel vs. vehicle). In like fashion, LPS-
matured BMDC also show enhanced metabolism in the presence of paclitaxel 
(Figure 3.6B; p<0.01 by Student‟s t-test; paclitaxel vs. vehicle). Figure 3.6C 
demonstrates that with increasing concentrations of LPS BMMØ metabolic activity 
increases. It is also apparent that a 10 µM dose of paclitaxel does not inhibit 
metabolic activity of BMMØ at any concentration of LPS, nor does the addition of 
LPS to paclitaxel treated BMMØ additively increase MTT reduction by BMMØ. 
That is, BMMØ are similarly metabolically active regardless of the LPS 
concentration. Previously it has been demonstrated that paclitaxel induces a dose 
dependent increase in metabolism in LPS-activated BMMØ (Crume et al., 2007). 
Thus, it is possible that at 10 µM, paclitaxel induces maximal metabolic activity by 
BMMØ, and the addition of LPS cannot increase MTT reduction further. Finally, it 
also follows that at lower concentrations, such as those used by Crume et al. 
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(Crume et al., 2007), paclitaxel and LPS may show additive effects on metabolic 
activity. 
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Paclitaxel exhibits dichotomous effects on BMMØ TNF-α production. (A) 
IFN-γ-primed BMMØ (5x104/well) were cultured with 10 µM paclitaxel or an 
equivalent concentration of ethanol (Vehicle). TNF-α production was measured in 
the supernatant by ELISA after 2 hours. *p<0.001; Student‟s t-test. (B) IFN-γ-
primed BMMØ (5x104/well) were activated with 2 ng/mL LPS in the presence of 
paclitaxel or an equivalent concentration of ethanol (Vehicle). After 8 hours the 
supernatant was assayed for TNF-α production by ELISA. Control TNF-α 
production was 17.453 ± 1.4125 ng/mL in this experiment. *p<0.001; One-way 
ANOVA with Bonferroni correction; Vehicle vs. Paclitaxel. Data points represent 
mean+SEM of duplicate wells from one of two similar experiments. 
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IFN-γ increases sensitivity of BMMØ to LPS. IFN-γ-primed (+ IFN-γ) or 
unprimed (- IFN-γ) BMMØ (5x104/well) were activated with LPS. (A) After 8 hours 
the supernatant was assayed by ELISA for TNF-α production. *p<0.01; Student‟s 
t-test vs. blank. (B) After 72 hours supernatants were assayed for nitric oxide 
production by the Greiss reaction. *p<0.05; **p<0.01; Two-way ANOVA with 
Bonferroni Correction, IFN-γ-primed vs unprimed. Data points and bars show 
mean+SEM of duplicate wells. 
 
Figure 3.2A Figure 3.2B 
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Duration of IFN-γ priming does not alter inhibition by paclitaxel. BMMØ 
(5x104/well) were primed with IFN-γ for various times prior to activation with 2 
ng/mL LPS in the presence or absence of 10 µM paclitaxel or an equivalent 
concentration of ethanol (Vehicle). (A) Bars represent mean+SEM of duplicate 
wells. (B) Bars represent mean+SEM of duplicate wells combined from two 
experiments. *p<0.05; **p<0.01; ***p<0.001; Paclitaxel vs. Vehicle, Two-way 
ANOVA with Bonferroni correction. 
Figure 3.3A Figure 3.3B 
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Paclitaxel does not cause an early shift in TNF-α production. IFN-γ-primed 
BMMØ (5x104/well) were activated with 2 ng/mL LPS in the presence of 10 µM 
paclitaxel or an equivalent concentration of ethanol (Vehicle). After 8 hours the 
supernatant was assayed by TNF-α ELISA. Data points represent mean+SEM of 
duplicate wells from one of three similar experiments (n=2) (A), all replicates were 
combined for values in (B) (n=6). *p<0.01; **p<0.001; Two-way ANOVA with 
Bonferroni correction.  
Figure 3.4B Figure 3.4A 
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Paclitaxel inhibits TNF-α and NO production by BMMØ at optimal responsive 
levels. IFN-γ-primed BMMØ (5x104/well) were activated with LPS in the presence 
or absence of 10 µM paclitaxel or an equivalent concentration of ethanol 
(Vehicle). After 8 hours the supernatant was assayed for TNF-α by ELISA (A). 
Cultures were incubated for a further 64 hours and assayed by the Greiss reaction 
for NO production (B). (A) Data points represent mean+SEM of duplicate wells 
from one of two similar experiments (n=2). (B) Data points represent mean+SEM 
of duplicate wells combined from two experiments (n=4 wells). LPS 
concentrations at which inhibition was seen were assessed for significance. 
*p<0.05;**p<0.01;***p<0.001; Paclitaxel vs. Vehicle by Two-way ANOVA with 
Bonferroni correction.  
Figure 3.5A 
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0.25 0.5 1 2 4 8 16 32 64 128 256
0
25
50
75
100
125
Vehicle
Paclitaxel
** ** **
***
***
ns
LPS (ng/mL)
N
it
ri
te
 %
 o
f 
c
o
n
tr
o
l
 56 
M
ed
iu
m
Ve
hi
cl
e
Pa
cl
ita
xe
l
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
*
A
b
s
o
b
a
n
c
e
 (
5
7
0
 n
m
)
M
ed
iu
m
V
eh
ic
le
P
ac
lit
ax
el
0.00
0.25
0.50
0.75 **
A
b
s
o
rb
a
n
c
e
 (
5
7
0
 n
m
)
0.25 0.5 1 2 4 8 16 32 64 128
0.0
0.1
0.2
0.3
0.4
Vehicle
Paclitaxel
*
********
LPS (ng/mL)
A
b
s
o
rb
a
n
c
e
 (
5
7
0
 n
m
)
  
 
  
 
 
 
 
 
 
 
 
 
 
 
Paclitaxel enhances metabolic activity of Bone-Marrow Derived Cells. IFN-γ-
primed BMMØ (5x104/well) (A) or LPS-matured BMDC (1x105/well) (B) were 
incubated for 72 hours in the presence or absence of 10 µM Paclitaxel or an 
equivalent concentration of ethanol (Vehicle) and subjected to the MTT assay. 
Bars show duplicate wells from one of three similar experiments (n=2). *p<0.01; 
Paclitaxel vs. Vehicle by Student‟s t-test. (C) IFN-γ-primed BMMØ were incubated 
for 72 hours with the stated concentrations of LPS in the presence or absence of 
10 µM paclitaxel or an equivalent concentration of ethanol (Vehicle). Data points 
represent mean+SEM of duplicate wells from one of two similar experiments 
(n=2). *p<0.01;**p<0.001; Paclitaxel vs. Vehicle by Two-way ANOVA with 
Bonferroni correction.  
Figure 3.6B 
Figure 3.6A 
Figure 3.6C 
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3.3 Discussion 
 
This study set out to determine why and how paclitaxel inhibits LPS-stimulated 
BMMØ TNF-α and NO production. An overnight stimulus of IFN-γ is commonly 
used as a stimulation step and requires 8-12 hours to fully augment LPS-
responsivity (Chung and Benveniste, 1990; Ma et al., 1996). The first experiments 
asked if there was interplay between IFN-γ priming and paclitaxel‟s inhibitory 
effect. If this was the case, we expected to see a shift in inhibition with extended 
priming duration. However, we found that when primed for 12-18 hours with IFN-γ, 
BMMØ production of TNF-α and NO was depressed by paclitaxel similarly at all 
time points. This finding suggests that paclitaxel does not cause a delay in the 
IFN-γ priming response. However, these assays did not examine the effects of 
paclitaxel on unprimed BMMØ. It would be interesting to determine if IFN-γ 
priming is requisite for inhibition, or if the pathways to production are depressed 
whether or not BMMØ are first stimulated with IFN-γ. 
  
Next we tested whether the drug was altering the temporal production of TNF-α. 
We postulated that a kinetic shift in production could induce an earlier peak in 
TNF-α production followed by a decrease in production by 8 hours. The results 
demonstrated that TNF-α increases with time in both drug-treated and vehicle-
treated cultures. However, by 6 hours TNF-α production in the presence of 
paclitaxel was lower than in control BMMØ. This difference persisted until the end 
of the assay indicating that production was inhibited by paclitaxel and did not peak 
early. 
 
Paclitaxel significantly reduced production of TNF-α and NO when BMMØ were 
stimulated with an optimal concentration of LPS. At low concentrations of LPS 
(<16 ng/mL) TNF-α production was inhibited by paclitaxel, but as LPS 
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concentrations increased, control BMMØ TNF-α production reduced to a basal 
level, masking paclitaxel‟s inhibitory effect. However, at all concentrations above 
16 ng/mL LPS, NO production was significantly inhibited by paclitaxel. The 
different dose-responses of TNF-α and NO may relate to differences in the 
processing of the agents once in the supernatant. Extracellular TNF-α can be 
removed from culture by BMMØ (Crume et al., 2007; Fujihara et al., 1994), 
whereas NO breaks down rapidly and accumulates in culture as nitrite and nitrate 
(Stuehr and Marletta, 1985; Stuehr and Marletta, 1987). Further, TNF-α is an early 
onset cytokine, while NO production occurs later (Sander et al., 1991; Stuehr and 
Marletta, 1987; Vila-del Sol et al., 2006). It would be of interest to investigate the 
production of both TNF-α and NO at intermediary timepoints when both agents 
are present, such as 16 or 24 hours. This may reveal more precisely how 
paclitaxel affects the two mediators simultaneously and shed light on the 
mechanisms involved in its inhibitory activity. Furthermore, investigating the 
interdependence of TNF-α and NO by adding antibodies to TNF-α and iNOS 
inhibitors such as aminoguanidine hemisulfate will determine the involvement of 
feedback within the system. 
 
The initial investigations by Crume et al. into the effects of LPS+paclitaxel on IFN-
γ-primed BMMØ showed that exposure to paclitaxel can lead to reduced levels of 
TNF-α and NO (Crume et al., 2007). The present study extends this finding by 
indicating that this reduction is likely due to mechanistic inhibition rather than 
kinetic alteration of TNF-α production. The mechanism by which this inhibition 
occurs is not clear; however, there are a number of functional levels at which 
paclitaxel may be interrupting the process. Some ways paclitaxel may affect the 
process include competitive interactions with TLR-4; inhibiting TNF-α secretion; 
and inhibiting signalling pathways. 
 59 
 
The first possibility is that paclitaxel directly inhibits the interaction of LPS with 
TLR-4. Paclitaxel is able to bind to and activate murine MD-2/TLR-4 complexes 
(Kawasaki et al., 2000; Kawasaki et al., 2001), so a mechanism of competitive 
inhibition for TLR-4 or other direct interactions may be involved. This possibility is 
unlikely for two reasons. Firstly, as peloruside demonstrates the same inhibitory 
properties as paclitaxel (Crume et al., 2007), it is likely that the microtubule 
network is involved in some way. Secondly, paclitaxel is seen to inhibit TNF-α and 
NO without altering IL-12p40 production, suggesting that the receptor is activated 
normally (Crume et al., 2007).  
 
An alternative is that TNF-α secretion is blocked when the microtubule network is 
stabilised. While TNF-α and IL-12p40 are induced by the same transcription 
factors and processed by the golgi apparatus prior to secretion (Baumgartner et 
al., 1996; Ma et al., 2004; Trinchieri, 1995), only LPS-induced TNF-α production is 
inhibited by paclitaxel (Crume et al., 2007). Recently it has been shown that TNF-
α release in MØ is controlled by the recycling endosome, and the phagosome is 
involved in its delivery to the recycling endosome (Manderson et al., 2007; Murray 
et al., 2005). There is evidence to suggest that suppressing microtubule dynamics 
with paclitaxel, colchicine or nocodazole causes inhibition of MØ phagosome 
movements and golgi transport (Blocker et al., 1998; Blocker et al., 1997; 
Peachman et al., 2004). It may be that by inhibiting these processes paclitaxel 
blocks TNF-α release. Furthermore, recycling endosome activity in T cells is 
inhibited by colchicine (Das et al., 2004), and if paclitaxel similarly represses 
recycling endosome activity in MØ it may directly inhibit TNF-α secretion. 
However, our results show that NO production is inhibited by paclitaxel at LPS 
concentrations where TNF-α production appears negligible. This does not rule out 
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that paclitaxel blocks TNF-α secretion but implicates other mechanisms in the 
inhibition of NO. 
 
Another possibility is that stimulatory signals activated by LPS were altered by 
paclitaxel. LPS can directly associate with β-tubulin and microtubule-associated 
proteins such as tau (Bohm et al., 1999; Ding et al., 1992). LPS also induces 
microtubule stabilisation and enhances associations of microtubule associated 
proteins with microtubules (Allen et al., 1997a; Allen et al., 1997b). Furthermore, 
LPS causes preferential phosphorylation of p42/44 MAP-K (Ding et al., 1996) 
which regulates TNF-α secretion (Rousseau et al., 2008). Thus, the microtubule 
network is known to be involved and modified by LPS signalling, which may 
partially explain why microtubule actives alter LPS-induced cytokine production. 
Assessing TNF-α mRNA levels in LPS-activated BMMØ treated with paclitaxel will 
indicate if signalling, or at least pre-translational processes are affected by the 
compound. Further, examining intracellular versus extracellular protein expression 
may also provide insight into how release is affected. Together these tools may 
determine the functional level of inhibition. 
 
TLR-4 signalling is also altered by DSD - Colchicine, nocodazole, podophyllotoxin 
and the vinca alkaloids affect MØ responses to LPS. These agents inhibit the 
LPS-induced formation of reactive oxygen species and NO, GM-CSF production 
and activity, and decrease TNF-α receptor, TNF-α protein and TNF-α mRNA 
expression (Allen et al., 1991; Ding et al., 1990a; Kirikae et al., 1996; Li et al., 
1996; Rammes et al., 1997; Rao et al., 1997). The similarities in the interactions 
make it tempting to speculate that the effects of MSD and DSD are causally 
related. If this is the case, it would suggest that a dynamic microtubule network is 
requisite to adequate signalling, release and effective MAP-K activity. In support 
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of this theory, paclitaxel and colchicine both inhibit TNF-α production, and also 
act to enhance IL-1β production following LPS stimulation (Allen et al., 1991; 
Crume et al., 2007; O'Brien Jr et al., 1995). Unlike TNF-α, IL-1β is not processed 
through the golgi apparatus but is instead cleaved from pro-IL-1β which 
associates with microtubules (Auron et al., 1984; O'Brien Jr et al., 1995; 
Stevenson et al., 1992). These different exocytosis pathways may determine the 
way the microtubule network affects cytokine production by BMMØ.  
 
We also investigated the metabolic activity of BMMØ in the presence of paclitaxel. 
As shown previously, paclitaxel increases BMMØ metabolic activity (Crume et al., 
2007). We saw that overall metabolic activity by BMMØ increased with LPS 
concentration. Basal metabolic activity of BMMØ is decreased by addition of low 
concentrations of LPS (c.f. Figure 3.6.A & 3.6.C) but increases with ramping LPS 
concentrations. Previous work by other groups suggests that the decrease is due 
to apoptosis induced by NO (Yamamoto et al., 1994).  Crume et al. showed that 
peloruside does not enhance BMMØ metabolic activity (Crume et al., 2007). 
Interestingly, in our experiments 10 µM paclitaxel induced the same metabolic 
activity irrespective of LPS concentration and it seems likely, as suggested 
previously (Crume et al., 2007), this may relate to its capacity to activate TLR-4. 
To determine if this alteration in metabolism correlates with changes in survival 
following LPS stimulation, looking at markers of apoptosis will be of value. Further, 
using LPS in combination with other ligands that stimulate TLR will help determine 
whether the increase in metabolic activity occurs in a TLR-dependent manner.  
 
We have investigated the responses of BMMØ to LPS in the presence of the MSD 
paclitaxel. Our results indicate that inhibition is not due to an early peak in 
production of TNF-α, is independent of the duration of IFN-γ priming and is only 
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observed at optimal LPS responsive levels, which differ for TNF-α and NO. We 
also demonstrate that metabolic activity of BMMØ and BMDC is significantly 
enhanced in the presence of paclitaxel. Taken together our findings demonstrate 
that BMMØ TNF-α and NO synthesis in response to LPS is inhibited and 
metabolic activity enhanced by paclitaxel. This in vitro modulation suggests that 
paclitaxel can affect the immune system in ways distinct from its anti-mitotic 
properties and may be clinically relevant to cancer patients fighting infection. 
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4 Involvement of the Microtubule Cytoskeleton in CTL 
Function 
 
4.1 Introduction 
 
Relocalisation of the MTOC to the IS is a prerequisite for CTL-mediated cell death 
(Kupfer et al., 1985). DSD inhibit this process and preclude cytolysis by CTL 
(Kupfer and Dennert, 1984; Wolberg et al., 1984). In addition to polarisation 
toward the TC, the microtubule cytoskeleton is involved in many steps of CTL-
mediated cytolysis. To induce TC death, the microtubule network is used as a 
scaffold along which lytic granules traffic en route to the IS (Stinchcombe et al., 
2001b). In synapsed CTL:TC conjugates, the CTL MTOC shows dynamic 
oscillations at the IS (Kuhn and Poenie, 2002). Further, actin microfilaments and 
microtubule plus-ends are cleared from the IS during lytic granule delivery, and 
there is evidence to suggest dynein-mediated transport is sufficient to deliver lytic 
granules to the IS (Kuhn and Poenie, 2002; Poenie et al., 2004; Stinchcombe et 
al., 2006). We were interested to investigate how MSD affect CTL lytic granule 
delivery, and to determine if peloruside and paclitaxel elicit different effects on 
CTL function. Specifically we asked if CTL-mediated cell death, degranulation and 
cytokine production are altered by in vitro treatment with paclitaxel or peloruside. 
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4.2 Results 
4.2.1 Short term paclitaxel treatment does not inhibit cytolysis in 
vitro 
 
To begin to determine effects of MSD on CTL-mediated cell death in vitro, we 
compared killing by CTL in the presence of paclitaxel, a vehicle control (0.1% 
ethanol) or medium alone at a range of CTL:TC ratios (50:1-0.4:1). Figure 4.1A 
shows that when CTL were combined with TC in the absence of peptide they were 
unable to kill target cells. However, when TC were pre-incubated with SIINFEKL 
peptide, specific lysis of the TC by CTL increased with higher ratios of CTL:TC. 
The addition of 0.1 µM or 1 µM paclitaxel did not inhibit specific lysis (p>0.05; 
Friedman‟s mean rank-sum test). Although the drug was present for the duration 
of the assay, we did not observe any effect on TC survival as measured by cpm of 
TC at the end of the assay (Figure 4.1B, p>0.05; One-way ANOVA). These results 
demonstrate that TC killing by CTL in vitro occurs effectively in the presence of 
paclitaxel. 
4.2.2 Pre-treatment with paclitaxel or peloruside does not inhibit 
CTL-mediated cell death in vitro 
 
Concentrations of paclitaxel and peloruside above 100 nM can induce microtubule 
bundling (Hood et al., 2002; Jordan et al., 1993). Brown et al. have demonstrated 
that a 4-hour pre-treatment with 1 µM paclitaxel induces microtubule bundles in 
the majority of CTL (Knox et al., 1993), and these bundles remain stable, even 
after washing until the cells enter mitosis (Brown et al., 1985). As we observed no 
effect of paclitaxel on CTL lytic capacity without pre-treatment, we examined 
killing under conditions that induce microtubule bundling, potentially amplifying the 
effects of MSD on CTL. Because microtubule bundles caused by MSD are stable 
after drug washout (Brown et al., 1985), we were able to compare killing at a wide 
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range of CTL:TC ratios with limited amounts of MSD. CTL were pre-treated for 
4 hours with 1 µM paclitaxel, 1 µM peloruside or an equivalent vehicle control 
(0.1% ethanol), washed and compared for their ability to lyse target cells in vitro. 
Figure 4.2A shows that, similar to the cytolytic assay in the continued presence of 
paclitaxel, a 4h pre-treatment with 1 µM peloruside or 1 µM paclitaxel did not 
inhibit CTL-mediated cytolysis in vitro (p>0.05; Friedman‟s mean rank-sum test). 
Additionally, we measured the metabolic activity of drug-treated CTL and saw no 
difference in the overall metabolism of CTL (p>0.05, One-way ANOVA). These 
results indicate that pre-treating CTL with MSD does not inhibit cytolysis of TC 
and is not directly cytotoxic to CTL. 
4.2.3 Paclitaxel and Peloruside do not inhibit degranulation by 
activated CTL 
 
Because FasL activity can compensate for deficiencies in the perforin/granzyme 
pathway (i.e., lytic granule delivery) (Lowin et al., 1994), and its expression does 
not require the microtubule network (He and Ostergaard, 2007), it was possible 
that increased FasL-induced apoptosis could mask any effect of MSD on lytic 
granule delivery. Thus, we directly assessed degranulation by measuring surface 
expression of the lysosomally-associated membrane protein CD107a (LAMP-1), 
which is indicative of lytic granule release (Betts et al., 2003). CD107a associates 
with lytic granules almost exclusively; however, during synthesis a small 
proportion transiently resides in the plasma membrane before trafficking to lytic 
granules (Carlsson and Fukuda, 1992), and thus can be detected at low levels on 
unactivated CTL.  
 
Colchicine has previously been shown to inhibit degranulation by CTL (Betts et 
al., 2003). As shown in Figure 4.3A&B, pre-treatment with 1 µM colchicine 
inhibited degranulation. However, without pre-treatment degranulation was not 
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inhibited. Because pre-treatment with colchicine was required to inhibit 
degranulation, we used a pre-treatment step in all subsequent degranulation 
assays.  
 
To determine the ability of lytic granules to traffic to the cell surface in the 
presence of MSD, CTL were pre-treated for 4 hours with 1 µM paclitaxel, 1 µM 
peloruside, 1 µM colchicine (as a positive control) or an equivalent vehicle control 
(0.1% ethanol), and then stimulated to degranulate. Neither paclitaxel nor 
peloruside inhibited degranulation by CTL (Figure 4.3C&D), whereas colchicine 
reduced degranulation by CTL at both 2 and 4 hours. Interestingly, pre-treatment 
with paclitaxel, peloruside or colchicine resulted in higher background MFI than 
control CTL (Figure 4.3A,C). We cannot explain why this occurs, but it may relate 
to CD107a trafficking or reinternalisation during synthesis (Carlsson and Fukuda, 
1992).  
4.2.4 Paclitaxel and Peloruside do not inhibit IFN-γ Production by 
activated CTL 
 
The signals leading to cytokine production and degranulation are differentially 
regulated in CTL (Faroudi et al., 2003; Wiedemann et al., 2006), and therefore 
may be uniquely susceptible to modulation by MSD. Because CTL produce large 
amounts of IFN-γ upon activation, in addition to degranulation and cytolysis, we 
investigated whether paclitaxel or peloruside altered IFN-γ production by CTL. 
However, while IFN-γ production was significantly inhibited by colchicine at both 2 
hours (Figure 4.4A; p<0.001) and 4 hours (p<0.01), it was not reduced by 
paclitaxel or peloruside (both p>0.05; Two-way ANOVA with Bonferroni correction, 
drug vs. vehicle). This suggests that pre-treating CTL with MSD does not inhibit 
their production of IFN-γ. 
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In parallel with assays of degranulation and IFN-γ production we examined 
metabolic activity of CTL. Neither paclitaxel nor peloruside altered metabolic 
activity, but some reduction in colchicine-treated cells was observed (Figure 4.4B; 
p<0.05, One-way ANOVA with Bonferroni correction, Colchicine vs. Vehicle). 
Together our data suggest that in the absence of anti-mitotic effects neither 1 µM 
paclitaxel nor 1 µM peloruside inhibit CTL-mediated cytolysis, degranulation or 
IFN-γ production in vitro. In contrast, colchicine, a known inhibitor of CTL function 
consistently reduced CTL degranulation, IFN-γ production and metabolic activity. 
4.2.5 Paclitaxel and Peloruside induce microtubule bundling in OT-
I T cells 
 
As we observed no effect of MSD on CTL activity we determined the extent to 
which the microtubule network was modified by our drug regimen. CTL were pre-
treated with 10 µM paclitaxel, 1 µM paclitaxel, 1 µM peloruside or 1 µM colchicine 
for 4 hours; adhered to coverslips for 30 minutes and stained for microtubules 
(green) and nuclei (blue). In control cells the microtubule network extends through 
the cytoplasm, radiating out from a dense core of microtubules which is likely to 
be the centrosome (Figure 4.5A,B). Examples of individual microtubules are 
demarcated by arrows. In contrast to control cells, 10 µM paclitaxel induces thick 
bundles of microtubules in almost all cells (Figure 4.5C; demarcated by asterisks). 
1 µM paclitaxel and 1 µM peloruside also induced microtubule bundling in CTL 
(Figure 4.5D,E), but less extensively than 10 µM paclitaxel. Pre-treating CTL with 
colchicine caused diffuse staining across the cytoplasm (Figure 4.5F; cell with 
arrow), indicating the presence of solubilised α/β-tubulin heterodimers. These 
results suggest that a 4-hour pre-treatment with MSD can induce microtubule-
bundling in CTL. However, because we observed stronger bundling at 10 µM 
paclitaxel than 1 µM it was possible that a high concentration (10 µM) of paclitaxel 
was required to alter degranulation and cytokine production by CTL.  
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4.2.6 10 µM Paclitaxel does not inhibit degranulation or IFN-γ 
production 
 
As the confocal microscopy results revealed extreme bundling in CTL pre-treated 
for 4 hours with 10 µM paclitaxel, we pre-treated CTL with 10 µM paclitaxel, 10 
µM colchicine or an equivalent vehicle control and assessed degranulation at 2, 4 
and 6 hours. As shown in Figure 4.6A&B even at this high dose of paclitaxel 
degranulation was not altered, but was reduced by 10 µM colchicine. 
Furthermore, similar to the effects on degranulation, production of IFN-γ was 
inhibited by 10 µM Colchicine, but not by 10 µM paclitaxel (Figure 4.6C). Further, 
10 µM paclitaxel did not alter CTL metabolism while 10 µM colchicine strongly 
reduced CTL metabolism (Figure 4.6D). These results support our previous 
findings that microtubule bundling does not inhibit peptide-induced degranulation 
or IFN-γ production by CTL. 
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Paclitaxel does not inhibit CTL-mediated cytolysis in vitro. CTL were 
subjected to a 4 hour JAM assay against SIINFEKL-pulsed (Ag+ TC) or control 
(Ag- TC) EL-4 target cells (TC) at various ratios in the presence of 0.1 µM 
paclitaxel, 1 µM paclitaxel, 0.1% ethanol (Vehicle) or medium alone. (A) % 
Specific Lysis was calculated as stated in the methods section. Lysis was specific 
to peptide-pulsed TC and did not differ significantly between the four treatments 
(p>0.05, Friedman‟s mean rank sum test). (B) In the absence of CTL, TC survived 
equally well with or without 1 µM paclitaxel as no loss of radioactivity (cpm) at the 
end of the assay was observed (p>0.05, One-Way ANOVA). This indicates that 
paclitaxel was not directly toxic to the TC. Data points represent mean+SEM of 
triplicate wells from one experiment. 
 
Figure 4.1A Figure 4.1B 
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Pre-treatment with Paclitaxel or Peloruside does not inhibit CTL-Mediated 
Cytolysis in vitro. CTL were pre-treated for 4 hours with 1 µM paclitaxel, 1 µM 
peloruside or 0.1% ethanol as control (Vehicle) and combined with TC at various 
ratios in drug-free media. (A) Specific lysis was calculated as stated in the 
methods section. In the absence of peptide (Ag- TC), no specific lysis was 
observed. In the presence of peptide (Ag+ TC), specific lysis was higher in wells 
with more CTL. Neither paclitaxel nor peloruside inhibited specific lysis at 4 hours 
(p>0.05, Friedman‟s mean rank sum test). (B) Metabolic activity of CTL was 
measured in parallel by the MTT assay. Neither paclitaxel nor peloruside caused a 
reduction in metabolic activity at the end of the assay (p>0.05, One-Way ANOVA). 
(A) Data points represent two to four wells from one of three similar experiments. 
(B) Data points represent triplicate wells from one of three similar experiments. 
Figure 4.2A Figure 4.2B 
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Paclitaxel and Peloruside do not inhibit degranulation in vitro. (A) CTL 
(1x105/well) were incubated with an antibody to CD107a with (solid lines) or 
without (dashed lines) SIINFEKL-peptide and assessed for their ability to 
degranulate as determined by MFI shift (B). All events were gated on CD8+ live 
cells. Purple shading shows vehicle-treated CTL background CD107a expression. 
When added at the same time as peptide (T=0), 1 µM colchicine did not alter 2 
hour degranulation compared to 0.1% ethanol (Vehicle). A 4-hour pre-treatment 
(T-4) with 1 µM colchicine inhibited degranulation at 2 hours. *p<0.001 One-way 
ANOVA with Bonferroni correction, Colchicine vs. Vehicle. Bars show mean+SEM 
of individual wells combined from two separate experiments. (C) CTL were pre-
treated for 4 hours with 1 µM paclitaxel (blue lines), 1 µM peloruside (green lines), 
1 µM colchicine (red lines) or 0.1% ethanol (vehicle; black lines) and subjected to 
2 hour 
4 hour 
CD107a Fitc 
CD107a Fitc 
Figure 4.3C 
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the degranulation assay as in (A). (D) Neither 1 µM paclitaxel nor 1 µM 
peloruside inhibited degranulation, whereas colchicine inhibited degranulation at 
both 2 and 4 hours. *p<0.01; Two-way ANOVA with Bonferroni correction, 
colchicine vs. vehicle. (D) Bars represent mean MFI shift + SEM of duplicate wells 
from one of three similar experiments; representative histograms from one such 
experiment are shown in (C).  
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Paclitaxel and peloruside do not inhibit IFN-γ production and are not 
immediately cytotoxic to CTL. (A) CTL (1x105/well) were pre-treated for 4 
hours with 1 µM paclitaxel, 1 µM peloruside, 1 µM colchicine or 0.1% ethanol 
(Vehicle) and then stimulated with SIINFEKL peptide. After 2 or 4 hours the 
supernatant was assayed for IFN-γ by ELISA. Neither paclitaxel nor peloruside 
inhibited IFN-γ production, whereas colchicine inhibited production at both 2 and 
4 hours. Without SIINFEKL peptide no IFN-γ was produced (data not shown). 
*p<0.01, **p<0.001, Two-way ANOVA with Bonferroni correction, colchicine vs. 
vehicle. Bars represent mean+SEM of two to four wells combined from three 
similar experiments. In one experiment 4-hour supernatants were discarded prior 
to analysis. (B) Following pre-treatment as in (A) CTL were subjected to the MTT 
assay as described in the methods section. Metabolic activity was not altered by 
paclitaxel or peloruside, but was reduced by colchicine. *p<0.05, One-way 
ANOVA with Bonferroni correction vs. vehicle. Bars represent mean+SEM of 
triplicate wells combined from three similar experiments. 
Figure 4.4A Figure 4.4B 
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Figure 4.5A - Vehicle 
Figure 4.5B - Vehicle 
Figure 4.5C- 10 µM Paclitaxel 
Microtubule Actives Modify the 
interphase CTL microtubule network. 
CTL were incubated for four hours in 
the presence of 0.1% ethanol, or the 
stated concentration of drug and 
subjected to immunocytochemistry. 
Microtubules were stained with rabbit 
anti-tubulin IgG and alexafluor-488 goat 
anti-rabbit IgG (green) and nuclei were 
identified using DAPI (blue). In control 
cells (A,B), individual microtubules 
(arrows) were seen extending through 
the cytoplasm. Some fragmented 
chromatin was observed, possibly an 
artefact of the sealing process. When 
treated with paclitaxel (C,D) or 
peloruside (E) microtubule bundles 
(asterisks) were observed. Bundling 
was more pronounced at 10 µM (C) 
than 1 µM paclitaxel (D) or 1 µM 
peloruside (E). In colchicine treated 
cells (F) diffuse staining (cell with arrow) 
was observed across the cell.  
→ 
→ 
* 
* 
* 
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Figure 4.5D- 1 µM Paclitaxel 
Figure 4.5E- 1 µM Peloruside 
Figure 4.5F- 1 µM Colchicine 
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(pink), paclitaxel (light blue) or colchicine (orange) without SIINFEKL peptide, or 
on exposure to SIINFEKL after pretreatment with vehicle (green), paclitaxel (dark 
blue) or colchicine (red). Paclitaxel did not inhibit degranulation (A,B), IFN-γ 
production (C), and had no effect on metabolism (D), while colchicine caused 
reductions in all three. (B,C) *p<0.001; Two-Way ANOVA with Bonferroni 
correction vs. vehicle. (D) *p<0.001 One-Way ANOVA with Bonferroni Correction 
vs. vehicle. (A) histograms are representative of duplicate wells from one of two 
experiments. (B-D) Bars show mean+SEM of two to four replicates from one of 
two similar experiments. 
 
10 µM paclitaxel does 
not affect CTL 
exocytosis in vitro. CTL 
(1x105/well) were pre-
treated for 4 hours with 10 
µM paclitaxel, 10 µM 
colchicine or vehicle (1% 
ethanol) and assessed for 
lytic granule release by 
the degranulation assay 
(A,B), IFN-γ production by 
ELISA (C), and survival by 
the MTT assay (D). (A) 
Histograms show CTL 
CD107a expression 2, 4 
and 6 hours after pre-
treatment with vehicle 
(pink) 
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4.3 Discussion 
 
The majority of work into MSD activity has focussed on their anti-mitotic properties 
and only more recently have the effects of these compounds on interphase cells 
been investigated. While the effects of paclitaxel on immune cells have been 
investigated to some extent, the immunological effects of peloruside are largely 
unknown. Currently, peloruside is known to kill proliferating splenocytes and to 
inhibit the LPS-induced production of TNF-α and NO, but not IL-12p40 (Crume et 
al., 2007; Miller et al., 1996). Additionally, Crume et al. showed that peloruside 
does not stimulate TLR-4 like paclitaxel (Crume et al., 2007). This thesis is the 
first study to look at the effects of peloruside on interphase CTL processes.  
 
Previously it has been shown that killing by murine CTL at high ratios of CTL:TC is 
unaffected by paclitaxel treatment, even at concentrations that induce bundling 
(Knox et al., 1993). In contrast, paclitaxel inhibits killing by human CTL (Chuang, 
1994; Chuang et al., 1994; Markasz et al., 2008). Because the study by Knox et 
al. utilized very high ratios of CTL:TC (50:1) and paclitaxel inhibited cytolysis by 
human CTL in vitro, we hypothesised that a more contact-limited system (lower 
CTL:TC ratio) may bring to light any subtle effects of paclitaxel on killing by murine 
CTL. Furthermore, we were interested to determine if effects of peloruside on CTL 
function were distinct from paclitaxel. 
 
When we examined killing in the presence of paclitaxel we saw no effect at high 
or low ratios of CTL:TC. Moreover, pre-treating CTL with paclitaxel or peloruside 
to induce microtubule bundling did not have any evident effects on killing, 
degranulation or IFN-γ production. Colchicine, as shown previously, inhibited 
degranulation, IFN-γ production and reduced cell metabolic activity (Betts et al., 
2003; Goldfinger et al., 1965; Ito et al., 1976). Given that DSD inhibit normal 
 78 
MTOC relocalisation in CTL (Kupfer and Dennert, 1984), it is not surprising that 
degranulation and IFN-γ production, like killing (Wolberg et al., 1984), were 
inhibited by colchicine.  
 
It is surprising, however, that CTL, even in the presence of high concentrations of 
MSD, were able to degranulate and kill TC effectively. The lack of inhibition 
argues that microtubule dynamicity is not essential in the killing process. Our 
confocal images show bundled microtubules in MSD-treated cells, but also 
demonstrate that microtubules still radiate out from the MTOC; this has previously 
been observed in CTL treated with paclitaxel (Knox et al., 1993). Furthermore, the 
MTOC can relocalise in CTL treated with paclitaxel, but not DSD, suggesting that 
this process is independent of microtubule dynamicity (Knox et al., 1993; Kupfer 
and Dennert, 1984). Lytic granules are associated with the peripheral microtubule 
network in unstimulated CTL (Stinchcombe et al., 2001b) and it is thought that 
delivery in stimulated CTL at least partially occurs in a dynein-mediated fashion 
(Kuhn and Poenie, 2002; Poenie et al., 2004; Stinchcombe et al., 2006). Thus, it 
appears that bundled microtubules operate as a sufficient scaffold for the 
transport of lytic granules. Because the concentrations of paclitaxel we used are 
well in excess (10-100 fold) of those required to inhibit dynamic instability in 
interphase cells (Jordan et al., 1993), our results and others (Knox et al., 1993), 
indicate that lytic granule delivery by murine CTL occurs sufficiently in the 
absence of a dynamic microtubule network. 
 
During killing the CTL MTOC becomes a particularly dynamic entity. As well as 
relocalising to the IS, when at the interface the MTOC often shows oscillatory 
movements both towards and across the IS (Kuhn and Poenie, 2002). In single 
CTL:TC conjugates, these oscillations occur exclusively at the IS; in CTL 
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conjugated to multiple TC large-scale migration of the MTOC is observed 
between the two (Kuhn and Poenie, 2002). The importance of MTOC motility with 
regard to lytic granule delivery is unknown. It has been suggested that dynein 
proteins are the driving forces that pull the MTOC through to the IS, and as such 
are important not only for lytic granule delivery, but also controlling these dynamic 
movements across the IS (Poenie et al., 2004). Based on our results it seems that 
if these oscillatory movements are involved in the killing process they occur even 
in CTL treated with MSD. Alternatively, these migrations may not be causatively 
involved in killing. Examining the microtubule network of MSD-treated CTL during 
killing in greater detail may elucidate the importance of these oscillations and how 
they are modified in the cell. 
 
The interactions at the IS leading to lytic granule exocytosis and stimulation of 
proinflammatory signalling pathways (i.e., production of IFN-γ) are differentially 
regulated in CTL. Lower TCR activation thresholds are required to elicit killing 
than cytokine production (Faroudi et al., 2003), and lytic granule delivery occurs 
more rapidly than large-scale TCR aggregation (Wiedemann et al., 2006). 
Colchicine inhibits recycling endosome activity in the human Jurkat T cell line 
resulting in lower TCR expression at the IS (Das et al., 2004), while, paclitaxel and 
vinblastine inhibit similar transport processes in MØ (Blocker et al., 1998). Thus it 
was possible that MSD could depress TCR expression and inhibit cytokine 
production by CTL without affecting degranulation. However, our results which 
measured degranulation and IFN-γ production simultaneously indicated that 
neither paclitaxel nor peloruside altered either process in activated CTL. 
Nevertheless, because at any given time only a small number of TCR are bound 
to ligand at the IS (Monks et al., 1998), it is possible that MSD do reduce CTL 
TCR recycling but such reductions were not sufficient to alter CTL activity. 
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Studies into the IS using the Jurkat T cell line and anti-CD3-coated coverslips 
show that microtubules are involved in stabilising the IS, and removal of 
microtubules with colchicine decreases the time for which an IS is maintained 
(Bunnell et al., 2001). Conversely, as colchicine decreases IS stability (Bunnell et 
al., 2001), inducing bundling may increase the duration of CTL:TC conjugation or 
increase the time it takes for signalling components to segregate appropriately in 
the IS (Grakoui et al., 1999; Monks et al., 1998). This increased contact time may 
explain why the overall rate of killing is reduced in human CTL (Chuang, 1994; 
Chuang et al., 1994; Markasz et al., 2008). However, the lack of effect we and 
others (Knox et al., 1993) observe in murine CTL suggests MSD affect CTL from 
mice and humans differently. Examining the real-time interactions of microtubules, 
lytic granules and IS components in MSD-treated cells may explain how CTL can 
elicit specific cell death with an altered microtubule network; explain why murine 
and human CTL are differently susceptible; and uncover effects of MSD on CTL 
that were not assessed in our experiments. 
 
Our results add to knowledge of the involvement of the microtubule network in 
CTL function in vitro to show that peloruside, like paclitaxel, does not inhibit 
specific lysis at high or low CTL:TC ratios; that both compounds induce bundling 
in CTL; and neither compound inhibits peptide-specific degranulation or IFN-γ 
production. Our results support work by others showing that MSD treatment does 
not inhibit murine CTL function in vitro. 
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5 Effects of Paclitaxel on CTL function in vivo 
5.1 Introduction 
 
There is a modest body of literature looking at modulation of the human immune 
system in vivo after systemic taxane therapy, including effects on plasma cytokine 
concentrations and alterations to cell populations. While general leukopenia 
occurs following taxane therapy (Tong et al., 2000), CD8+ T cells show a degree 
of resistance to the cytotoxic effects of MSD, and ex vivo responses of the CTL 
population actually seem to be enhanced after therapy cessation (Westerterp et 
al., 2008; Zhang et al., 2008). One study showed that CD8+/IFN-γ+ T cell 
responses are associated with decreased tumour burden, and these responses 
are enhanced following combination carboplatin/paclitaxel therapy (Coleman et 
al., 2005). In another study, both CD8+/IFN-γ+ and (activated) CD44+/CD8+ T cells 
were more numerous in patients after paclitaxel therapy (Zhang et al., 2008). A 
recent study investigated the effects of Taxol on the CTL response 2 days post 
therapy, and saw no change in the baseline killing of TC after 16 hours (Vicari et 
al., 2009). Because Taxol has an in vivo half-life of 0.8 hours (Zhang et al., 1997), 
and therefore may no longer be at an effective concentration 2 days post therapy, 
we analyzed the immediate in vivo effector response of CD8+ T cells following 
drug administration.  
5.2 Overview of the In vivo Cytolytic Assay 
 
To induce an antigen-specific CTL response in vivo, mice were injected with LPS-
matured, SIINFEKL peptide-pulsed BMDC to immunise mice. One week later 
mice were administered a single intraperitoneal dose of 20 mg/kg Taxol and 
approximately 2 hours later injected intravenously with 8x106 syngeneic 
splenocytes as TC. The TC contained an equal mix of carboxyfluorescein 
succinimidyl ester (CFSE)-labelled SIINFEKL+ (Ag+) TC and Cell Tracker 
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Orange® (CTO)-labelled control (Ag-) TC. After 10 hours, the mice were 
euthanized, their spleens removed and stained for CD8, and the % specific lysis 
was calculated by comparing the survival of Ag+ TC relative to Ag- TC. For 
example, if Ag- specific lysis occurred in vivo, fewer Ag+ TC would be recovered 
compared to Ag- TC.  
 
To determine if Ag-specific CTL survival was altered by Taxol treatment, mice 
received 1x106 congenic OT-I/ptp-rca lymph node cells one day prior to 
immunisation. OT-I/ptp-rca T cells express clonal Vα2/Vβ5.1/5.2-TCRs specific for 
the SIINFEKL peptide, and are CD45.1+/CD45.2+. Because the recipient C57BL/6 
mice T cells are exclusively CD45.2+ we can track the OT-I/ptp-rca population by 
examining CD45.1 expression. As the TCR of the adoptively-transferred 
population is SIINFEKL-specific, these cells should predominate the immune 
response following immunization, allowing us to closely monitor the effector CTL 
in vivo. Following euthanasia splenocytes were examined for CD8 and CD45.1 
expression alongside Ag+/Ag- TC survival. 
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5.3 Results 
5.3.1 Taxol Inhibits Immediate Cytolysis in Mice 
 
Because in vitro assays are highly optimized and tightly controlled, it was possible 
that in the more limiting and variable in vivo setting moderate alterations in CTL 
function would be more evident. During their proliferative phase, the CTL 
population expands rapidly, reaching a stage where cells divide on average every 
5-9 hours (De Boer et al., 2001; Hwang et al., 2006; Oehen and Brduscha-Riem, 
1998). However, maximal numbers of CTL are generated around day 6 after 
which proliferation slows and becomes minimal by day 7 (De Boer et al., 2001). 
Our immunisation strategy was set in a window that allowed mice to generate a 
potent CTL response, while avoiding any anti-mitotic effects of Taxol. To further 
minimise anti-mitotic effects, we examined cytolysis in a short time period (10 
hours) which has previously been shown to be sufficient to detect killing (Hermans 
et al., 2004).  
 
Immunising mice with BMDC pulsed with 1 µM SIINFEKL peptide generated a 
strong anti-SIINFEKL response causing specific depletion of the Ag+ TC 
population (Figure 5.1A; p<0.01 by One-way ANOVA with Bonferroni correction; 
Immunised vs. Unimmunised within drug treatment). Differences in Ag+ TC 
survival in unimmunised groups were minimal (p=0.100; Effect of Drug alone by 
Two-way ANOVA; data not shown); nevertheless, to account for any non-specific 
effect of Taxol we normalised killing within a drug treatment. In contrast to the in 
vitro results, in vivo treatment with 20 mg/kg Taxol caused a reduction in CTL-
mediated cytolysis (Figure 5.1A; p<0.05; One-way ANOVA with Bonferroni 
correction, Taxol vs. Vehicle, Immunised Groups). While our system was 
designed to reduce the anti-mitotic effects of Taxol, a decrease in effector CTL 
numbers would explain the reduced cytolysis in drug-treated mice. However, 
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examining CD8+ T cell numbers, of which the effector CTL will form a subset, no 
difference was observed between any groups (p>0.05; One way ANOVA with 
Bonferroni correction; Figure 5.1B). Thus, our data suggest that Taxol inhibits 
CTL-mediated cytolysis in vivo without significant effects on survival of the CD8+ 
population. 
5.3.2 Taxol does not deplete the effector population in vivo 
 
Our initial data suggested that Taxol did not inhibit cytolysis by killing CD8+ 
splenocytes. However, as effector CTL comprise only a subset of all CD8+ T cells, 
it was possible that the background CD8+ population was masking a depletion of 
Ag-specific CTL by Taxol. We redesigned our experiment to include the adoptive 
transfer (AT) of OT-I/ptp-rca lymph node cells prior to immunisation, which should 
then predominate the SIINFEKL-specific CTL response. As expected, 
immunisation increased numbers of CD8+/CD45.1+ T cells (Figure 5.2A) and 
greatly enhanced specific lysis (Figure 5.2B) in immunized mice. 
 
To determine the effects of Taxol on CTL survival in vivo we administered mice an 
intraperitoneal dose of 20 mg/kg Taxol or an equivalent dose of Cremophor EL® 
and submitted them to a 10 hour VITAL assay. As shown in Figure 5.3A, Taxol 
treatment did not deplete the CTL population. Further, Taxol caused a small 
reduction in specific lysis that did not reach significance in this assay (Figure 
5.3B), which may relate to low animal numbers in each group. This lack of effect is 
contrary to the results of Figure 5.1 A. Moreover, mean cytolysis at 10 hours in 
experiments where control mice received transgenic T cells prior to immunisation 
was higher than in experiments where they did not (c.f. Figure 5.1A & 5.3B; 
p<0.05, Student‟s t-test, shown again in Figure 5.3C). Because mice with 
transgenic T cells potently eliminated SIINFEKL-specific TC, the kinetics of 
cytolysis may be more rapid in this system, so earlier timepoints may be more 
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appropriate when using OT-I/ptp-rca T cells. Furthermore, Taxol possesses only 
a short half-life in vivo (0.8 hours) and is rapidly eliminated from tissues, including 
the spleen (Zhang et al., 1997). We reasoned that a higher bolus dose of Taxol 
may inhibit CTL responses for longer periods, which would exaggerate inhibition 
at earlier timepoints. Further, higher drug concentrations would accentuate any 
residual anti-mitotic effects on the effector population. Thus, we repeated the 
adoptive transfer experiment and treated mice with 30 mg/kg Taxol (0.75 
mg/mouse) and examined killing of Ag+ TC after 8 hours.  
 
Even with this high drug concentration the CTL population was not depleted in 
drug-treated mice (Figure 5.4A; p=0.5753; Student-s t-test, Taxol vs. Vehicle, 
Immunised groups). Specific lysis was inhibited by Taxol to a similar level as 
previous experiments (Figure 5.4B), although this difference did not reach 
statistical significance (p=0.0988; Student‟s t-test, Taxol vs. Vehicle, Immunised 
groups), we again believe this is most likely due to the low numbers of animals in 
each group. In support of this supposition, when we combined mice treated with 
Taxol at either dose, we still did not observe any effect on CTL survival (Figure 
5.4C, p=0.4322), whereas combining the groups did lead to a detectable 
difference in cytolysis (Figure 5.4D, p=0.0329; Student‟s t-test, Vehicle vs. Taxol, 
immunised groups). To further clarify if the number of CTL was directly related to 
the level of killing, we correlated the numbers of OT-I/ptp-rca CTL to % specific 
lysis in all mice from both experiments (Figure 5.5). Although the number of CTL 
was not related to % specific lysis in vehicle-treated mice (r2=0.2420), there was a 
significant relationship between CTL number and % specific lysis in Taxol-treated 
mice (r2=0.7049; linear regression analysis). Further, the relationship between 
CTL number and % specific lysis was significantly different in Taxol-treated and 
vehicle-treated immunised mice (p<0.05; linear regression F-test for difference in 
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slope). Thus, these results suggest that under conditions where CTL numbers 
are limiting, Taxol exerts the greatest inhibition on their function. Together these 
data support the hypothesis that inhibition of CTL-mediated cytolysis in vivo is due 
to functional inhibition of CTL rather than cytotoxic effects on the effector 
population.  
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Taxol inhibits CTL-Mediated Cytolysis without depleting CD8+ cells in vivo. 
C57BL/6 mice were immunised as described in general methods. One week later, 
mice were injected intraperitoneally with 20 mg/kg Taxol or an equivalent vehicle 
control (Cremophor EL®) and subjected to a 10-hour VITAL assay. Specific lysis 
(A) and numbers of CD8+ splenocytes (B) were calculated as described in the 
general methods section. Data points represent individual mice pooled from three 
separate experiments; lines represent group means. (A) *p<0.05; One-way 
ANOVA with Bonferroni correction, Taxol vs. Vehicle, Immunised Groups. (B) No 
difference in total CD8+ number was detected (p>0.05; One-Way ANOVA). 
Figure 5.1A 
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Immunisation Expands the Adoptively-Transferred Population and Permits 
Specific Lysis. Prior to immunisation mice received 1x106 OT-I/ptp-rca lymph 
node cells. One week later mice were given an intraperitoneal dose of Cremophor 
EL® or Taxol and subjected to the VITAL assay. (A) Total CD45.1+/CD8+ numbers 
(A) and specific lysis (B) were determined as described in general methods. Bars 
represent mean+SEM from all immunised mice combined from two experiments, 
shown individually in Figure 5.3A&B and Figure 5.4A&B. *p<0.001, Student‟s t-
test Immunised vs. Unimmunised. 
 
 
 
 
 
 
 
 
 
 
 
 
Immunised Unimmunised
0
25
50
75
100
*
%
 S
p
e
c
if
ic
 L
y
s
is
Figure 5.2B 
Immunised Unimmunised
0
25000
50000
75000
100000
125000
150000
175000 *
#
 C
D
4
5
.1
+
/C
D
8
+
 S
p
le
n
o
c
y
te
s
Figure 5.2A 
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did not receive (C57BL/6) transgenic T cells prior to immunisation shown in 5.1A 
and 5.3B are represented here by bars showing mean+SEM. Mice that received 
transgenic T cells prior to immunisation eliminated TC to a greater extent than 
C57BL/6 mice that did not (*p<0.05, Student‟s t-test). 
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Figure 5.3A Taxol does not deplete 
CD45.1+/CD8+ CTL in vivo. Prior to 
immunisation as described in 
general methods mice received 
1x106 OT-I/ptp-rca lymph node cells. 
One week later mice were given an 
intraperitoneal dose of 20 mg/kg 
Taxol or an equivalent dose of 
Cremophor EL® as vehicle control. 
Two hours later mice were subjected 
to a 10 hour VITAL assay. Total 
numbers of CD45.1+/CD8+ CTL (A) 
and specific lysis (B) were 
calculated as described in general 
methods. Data points represent 
individual mice; lines represent 
group means. Killing was not 
significantly inhibited in this assay 
(p>0.05, Student‟s t-test; Immunised 
groups). (C) Killing in vehicle-treated 
mice that received (OT-I/ptp-rca) or 
did  
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Taxol does not deplete CTL and inhibits CTL-Mediated Cytolysis in vivo. 
Prior to immunisation, mice received 1x106 OT-I/ptp-rca lymph node cells. (A,B) 
One week after immunisation mice were given an intraperitoneal dose of 30 mg/kg 
Taxol or an equivalent dose of Cremophor EL® as vehicle control. 2 hours later 
mice were subjected to an 8 hour VITAL assay. Total numbers of CD45.1+/CD8+ 
CTL (A) and specific lysis (B) were calculated as described in general 
methods.(C,D) Immunised mice analysed separately in Figure 5.3A,B and Figure 
5.4A,B were combined and analysed together. Data points represent individual 
mice; lines represent group means. *p<0.05, Student‟s t-test, Taxol vs. Vehicle. 
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Figure 5.5 
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Taxol inhibits CTL-mediated cytolysis in mice with similar numbers of CTL. 
Numbers of CD45.1+/CD8+ CTL in mice shown in Figure 5.4C were correlated to 
specific lysis in Figure 5.4D. Between immunised groups, Taxol-treated mice 
showed reduced lytic capacity compared to Vehicle-treated mice with similar 
numbers of CD45.1+/CD8+ CTL. Dots show individual mice, lines show the group 
trends, which differ for Taxol- and Vehicle-treated mice (p<0.01; Taxol vs. Vehicle, 
Immunised groups; F-test for difference in slope)  
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5.4 Discussion 
 
We set up two complementary systems to measure the effects of Taxol on CTL 
functionality in vivo. In the first, we examined the effect of drug on the autologous 
host response to SIINFEKL peptide. Our results showed that a single 20 mg/kg 
dose of Taxol inhibited CTL-mediated cytolysis in vivo. A second system, the 
adoptive transfer of OT-I/ptp-rca lymph node cells into C57BL/6 recipients, allowed 
us to monitor survival of the effector population and lytic activity simultaneously. In 
these studies immunisation caused the expansion of CD45.1+/CD8+ cells in the 
spleens of mice and the presence of this population correlated well with cytolysis 
in vivo. Further, similar numbers of CD45.1+/CD8+ CTL were detected in mice 
treated with Cremophor EL® and Taxol. However, control mice appeared better 
able to eliminate TC than Taxol-treated mice. Taken together our data suggest 
Taxol inhibits CTL activity in vivo and this occurs independently of Taxol‟s anti-
mitotic properties. 
 
In line with our work, Vicari et al. recently reported an inhibitory effect of Taxol on 
CTL-mediated cytolysis in vivo.(Vicari et al., 2009) In a solid-tumor cancer model, 
this study initially showed paclitaxel enhanced the anti-tumour response in a 
CD8+-dependent manner.(Vicari et al., 2009) However, when mice were given a 
TLR-9 agonist and tested for their ability to kill SIINFEKL-pulsed splenocytes (as 
TC), paclitaxel limited killing to levels of control mice (≈10%). In this experiment 
both paclitaxel and the immune adjuvant (PF-3512676) were administered 2 days 
prior to TC transfer, so it may be that paclitaxel depressed the enhancement 
conferred by the TLR-9 agonist, rather than inhibiting CTL:TC killing. In contrast, 
our studies aimed to determine the immediate effects of paclitaxel on cytolysis in 
vivo. 
 93 
  
In our adoptive transfer (AT) experiments mice given a 30 mg/kg dose of Taxol 
exhibited impaired killing versus controls at 8 hours. When we assessed the 
effects of a 20 mg/kg dose at 10 hours, the difference was less pronounced. We 
resolved that this was likely due to the kinetics of cytolysis. As suggested by 
others (Hermans et al., 2004), if killing plateaus as TC become sparse, differences 
will be best detected during the exponential phase of cytolysis in control mice. In 
experiments assessing the host-generated immune response, 10 hours provided 
a window in which differences in specific lysis between control and drug treated 
mice were detected. However, mice that contained OT-I/ptp-rca CTL appeared to 
eliminate the target population to a greater extent than C57BL/6 heterologous 
responders, leading to more pronounced effects of drug at 8 rather than 10 hours.  
 
Kinetically, Taxol may affect killing in two independent but not mutually exclusive 
ways. Firstly, at early times, high concentrations of drug may ablate killing, but as 
the drug concentration reduces, killing rates return to those of controls (Figure 
5.6). Secondly, following drug exposure, killing may be depressed such that the 
rate of killing is reduced relative to controls (Figure 5.7). Taxol is eliminated 
relatively rapidly in vivo, with a half-life of approximately 0.8 hours (Zhang et al., 
1997), but accumulates in tissues such as the spleen when administered 
continuously (Klecker et al., 1994). If the effects of Taxol are transient, then 
differences in specific lysis will best be determined at early times before the effect 
of drug wears off. Alternatively these effects will be amplified with multiple 
administrations of drug. Conversely, if Taxol operates by reducing the rate of lysis, 
inhibition will be most exaggerated at times just prior to plateau in control mice. 
These two possibilities could be distinguished by maintaining a constant level of 
drug and by assessing cytolysis at multiple timepoints. 
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While our results indicate that paclitaxel inhibits CTL function in vivo, Taxol does 
not necessarily affect CTL directly. Because our in vitro results indicate that in 
murine CTL, the process of lytic granule exocytosis is not inhibited by MSD, it is 
likely that other microtubule-dependent processes are involved in the inhibition of 
CTL function caused by Taxol in vivo. These alternative explanations include 
altered tissue homing of cells; changes to the surface phenotype of TC; increased 
CTL:TC conjugation periods; and modification of the signals between CTL and 
TC.  
 
As CTL-mediated cytolysis is contact dependent, CTL must encounter TC to 
induce specific lysis. Thus, Taxol may alter the migratory properties of either CTL 
or TC. Previous studies have shown that systemic Taxol administration inhibits 
LPS-induced neutrophil extravasation, vascular leakage and protects mice from 
septic shock (Mirzapoiazova et al., 2007). Further, Taxol ablates the expected 
leukocyte infiltration into the peritoneum following LPS administration 
(Mirzapoiazova et al., 2007). Even slight modifications to cell migratory properties 
could alter the ability of CTL to interact with TC. Depending on the tissue 
localisation of the targets, paclitaxel may prevent CTL from coming into contact 
with TC. As we measure lysis and survival in the spleen, it seems unlikely that the 
populations are prevented from mixing. However, as effector CTL traffic through 
the periphery is more than naïve T cells (Wherry et al., 2003), and approximately 
30% of our in vivo TC will be naïve T cells (Garnett et al., 2008), it is possible that 
paclitaxel alters tissue homing and reduces the rate of encounter of the two cell 
types prior to final analysis in the spleen. 
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An alternative explanation is that paclitaxel modifies the target cell, such that 
the intercellular signals that lead to target cell death are hindered. In order to 
induce lysis, protein signalling between CTL and TC must be strong enough to 
form a stable immunological synapse (IS), activate the TCR and polarise the CTL 
to kill the TC. If the ability of CTL to recognise TC is compromised then the 
formation of the synapse will be inhibited. In support of this, pre-treatment of 
murine cell lines with paclitaxel reduces surface expression of CD11a and CD54 
(Zhao et al., 2003), both of which are involved in stabilisation of the IS (Monks et 
al., 1998; Stinchcombe et al., 2001b; Stinchcombe and Griffiths, 2003; 
Stinchcombe et al., 2006). This decreased expression directly correlates with 
reduced lysis of the cells by CD3-activated lymphocytes (Zhao et al., 2003). If 
such modifications have an effect in vivo, cytolysis will be inhibited.  
 
Also concerning the interaction between CTL and TC, the ability of CTL to kill 
multiple targets in vivo may be impeded. In human CTL in vitro it has been shown 
that while CTL readily conjugate and elicit cell death in individual TC, their ability 
to recycle and kill multiple targets is greatly limited by paclitaxel (Chuang, 1994; 
Chuang et al., 1994). Similar to the in vitro setting, CTL in vivo are likely to kill 
multiple TC either serially or simultaneously (Breart et al., 2008), so inhibition of 
the rate of cytolysis may explain the decreases in killing we observe in mice in 
vivo. 
 
As well as modulation of intercellular adhesion, the stimulatory signals leading to 
formation of the IS may be depressed by Taxol. For example, paclitaxel has been 
shown to inhibit DC stimulation of T cell proliferation in vitro by effects on the DC, 
even though the DC have elevated MHC-II expression (Joo, 2003). The ability to 
form and stabilise an IS is heavily dependent on the strength of interaction 
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between TCR and MHC-peptide complexes (Grakoui et al., 1999), rather than 
the number of bound TCR (Monks et al., 1998). If Taxol inhibits the interaction of 
TCR-MHC-peptide, the drug may have some effect on the ability of CTL to induce 
death of TC. Transient interactions such as these could be more important for 
interactions of CTL and TC  in vivo than in vitro. 
 
Our study contrasts a number of reports in humans and mice suggesting 
enhanced CD8+ T cell function following paclitaxel treatment. In humans, reports 
suggest that IFN-γ-secreting CD8+ T cells are more numerous after therapy; 
activated (CD44High) CD8+ T cells are more frequent and TREG are specifically 
inhibited by Taxol (Zhang et al., 2008). This depletion is important because TREG 
directly suppress CTL activity in vitro and in vivo; in the absence of TREG, CTL 
activity is increased (Mempel et al., 2006; Vicari et al., 2009). Moreover, the CD8+ 
subpopulation of lymphocytes is enriched in cancer sufferers and has been 
reported to either recover rapidly following or be minimally depleted by paclitaxel 
treatment (Tong et al., 2000; Westerterp et al., 2008). However, in contrast to our 
experiments, these reports generally measure cell function following cessation of 
therapy, so these effects may relate to leukopenia caused by Taxol.  
 
Murine studies demonstrate that as immune adjuvants, paclitaxel and docetaxel 
enhance anti-tumour responses. Using either DC therapies or GM-CSF-based 
vaccinations, CD8+ T cell function and CD8+-IFN-γ production are enhanced by 
paclitaxel (Chu et al., 2006; Garnett et al., 2008; Yu et al., 2003); CD4+ and CD8+ 
T cell tumour infiltration increase (Zhong et al., 2007); and epitope spreading is 
induced (Garnett et al., 2008). Most importantly, however, in combination with 
immunotherapies, taxanes inhibit tumour growth and increase progression-free 
survival (Chu et al., 2006; Emens et al., 2001; Garnett et al., 2008; Machiels et al., 
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2001; Vicari et al., 2009; Yu et al., 2003; Zhong et al., 2007). Reactivation of the 
tumour-specific immune response with chemotherapeutics seems a promising 
avenue for effective cancer treatment, particularly considering the positive results 
of such studies. However, our results show that immediate effector function is 
inhibited by Taxol prior to the observation of any anti-mitotic effects.  
 
Our system was not designed to measure the anti-tumor response, but rather the 
immediate cytolytic response to infection of CD8+ T cells. CTL-mediated cytolysis 
is drastically modified by the tumor micro-environment, and the interactions of 
CTL with tumor cells differ from those with individual TC (Breart et al., 2008; 
Mempel et al., 2006; Radoja et al., 2001; Vicari et al., 2009). We suggest that any 
enhancing effects of paclitaxel on the CD8+ T cell population will not be 
immediate, and before complete leukocyte recovery, the host immune system will 
be impaired in its ability to fight infection and elicit specific cell death in vivo.  
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Figure 5.6 
 
Theory pertaining to in vivo inhibition by Taxol 1: Killing is blocked while Taxol 
is present at significant levels, but killing returns to normal rates after drug is 
removed from the host. By 8 hours, control mice (in adoptive transfer 
experiments) have removed the majority of the TC population and killing reaches 
a plateau. Drug-treated mice at 8 hours are killing TC at a higher rate than 
controls, so the difference between the two reduces as time continues. 
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Figure 5.7 
 
Theory pertaining to in vivo inhibition by Taxol 2: Killing is functionally 
inhibited in drug treated mice. Killing occurs at a consistent but reduced rate 
compared with control mice and does not recover with drug washout. Killing will 
reach a plateau phase, but at delayed times in the presence of drug. 
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6 General Discussion 
 
6.1 General Summary of Work 
 
This thesis set out to determine the functional immunological effects of MSD. It 
specifically investigated effects of MSD on exocytic function in immune cells. 
BMMØ are a terminally differentiated cell type and thus are not susceptible to the 
anti-mitotic effects of MSD (Crume et al., 2007). Degranulation is an interphase 
CTL process that heavily involves the microtubule network (Mempel et al., 2006; 
Stinchcombe et al., 2001b; Stinchcombe et al., 2006) and could be examined 
while avoiding the anti-mitotic effects of MSD. 
 
The current study continued work in our lab showing that BMMØ production of 
TNF-α and NO are inhibited by MSD (Crume et al., 2007). It investigated the 
involvement of IFN-γ stimulation in the inhibition; assessed the kinetics of TNF-α 
production in the presence of paclitaxel; and addressed why the stimulating dose 
of LPS affects paclitaxel‟s inhibitory effect on TNF-α production. Furthermore, our 
research expanded knowledge of how TLR-4 activation alters cellular metabolic 
activity. The results of the current study implicate functional inhibition and largely 
exclude kinetic alteration as the mechanism behing MSD-mediated supression of 
BMMØ inflammatory responses.  
  
Of particular note we observed different LPS-dose responses for BMMØ 
production of TNF-α and NO, which led to different inhibitory relationships with 
paclitaxel. With increased concentrations of LPS, NO production plateaued, 
whereas TNF-α reduced to a basal level. Similar LPS dose-response curves for 
TNF-α and NO have been observed previously (Kastenbauer and Ziegler-
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Heitbrock, 1999; Shnyra et al., 1998; Stuehr and Marletta, 1985; Stuehr and 
Marletta, 1987; Takasuka et al., 1991). This refractiveness for TNF-α appears to 
be important in BMMØ responses to LPS and helps explain why paclitaxel does 
not inhibit TNF-α production above 20 ng/mL as seen in the work by Crume et al. 
(Crume et al., 2007).  
 
Similar to MØ responses to LPS, CTL-mediated cytolysis occurs after cell division 
and thus provided an alternative system in which to investigate the functional 
effects of MSD on immune processes. Furthermore, MØ and CTL are both key 
components of the cell-mediated immune response, which makes examining CTL 
and MØ together beneficial to the understanding of the wider immunological 
implications of MSD therapy.  
 
In this thesis, the results from in vitro work using CTL supported work by others 
(Knox et al., 1993) showing that concentrations of paclitaxel that induce 
microtubule bundling do not inhibit killing by murine CTL in vitro. The current study 
extended these findings to show that neither degranulation nor IFN-γ production 
by CTL were inhibited by paclitaxel treatment. Furthermore, this was the first study 
to assess the effects of peloruside on interphase CTL processes. Like paclitaxel, 
peloruside showed no inhibitory effect on CTL killing, degranulation or IFN-γ 
production in vitro and also induced microtubule bundling in CTL, albeit to a lesser 
extent than paclitaxel.  
 
Perhaps the most significant result of this thesis was attained in a murine model of 
CTL-mediated cytolysis. Investigating CTL-mediated TC death in vivo revealed an 
inhibitory effect of paclitaxel that was not apparent in vitro. Importantly, this 
occurred in the absence of anti-mitotic effects on the CTL population. This is the 
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first study (to the knowledge of the author) to assess the immediate effects of 
paclitaxel on CTL-mediated cytolysis in vivo. We believe it provides new 
information relevant to patients undergoing taxane therapy, and illustrates the 
importance of using in vivo models in the search for less invasive and increasingly 
effective treatments for cancer.  
 
It is important to consider that the interactions of CTL and TC in the tumor micro-
environment differ to those in lymphoid tissue (Breart et al., 2008; Mempel et al., 
2006), so the data may not apply directly to anti-tumour responses, but rather be 
more relevant to CTL-dependent control of infection during MSD treatment. 
Increased risk of infection following MSD therapy is generally associated with the 
anti-mitotic effect of the drugs (Iura et al., 2009; Souglakos et al., 2002). The 
current study supports work by others (Chuang et al., 1994; Crume et al., 2007; 
Markasz et al., 2008) demonstrating functional inhibition of both CTL and MØ 
responses by paclitaxel. Collectively these results suggest that the increased risk 
of infection during paclitaxel therapy may occur in part due to functional effects, 
and not solely anti-mitotic effects of the compound. 
 
Knowledge of how the immune system is modified by chemotherapeutics is 
becoming more important, particularly with increasing investigation into co-
immuno-chemotherapies. Numerous recent studies identify enhancement of the 
anti-cancer immune response by taxanes both clinically and in murine models 
(Garnett et al., 2008; Machiels et al., 2001; Vicari et al., 2009; Westerterp et al., 
2008; Yu et al., 2003; Zhang et al., 2008; Zhong et al., 2007). These studies 
generally assess immune responses following cessation of therapy, whereas the 
current study looked at immune responses during MSD treatment. The results of 
the current thesis suggest that immediate functional repression of CTL can occur 
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during MSD treatment in vivo. Hopefully a better understanding of the 
immediate and long-term benefits and risks of MSD treatment will allow for 
improved quality of life and longer progression-free survival for cancer patients.  
 
As we understand more about the immunological implications of MSD treatment, 
we are not only better able to limit and control undesirable side effects, but can 
also find other clinical applications for the drugs. Repressing the immune system 
can be desirable in settings outside of cancer. The anti-mitotic properties of MSD 
have already been exploited in a murine model of multiple sclerosis (Cao et al., 
2000), and utilised clinically to limit in-stent restenosis (occlusion of a stent by 
tissue regrowth) (Tanabe et al., 2003). Furthermore, paclitaxel has been shown to 
block cell extravasation and vascular leakage during murine LPS-induced sepsis 
(Mirzapoiazova et al., 2007), suggesting MSD have the potential to prevent 
cytotoxicities involving aberrant cell trafficking. It is important, however, to 
consider the currently unavoidable toxic effects of high doses of MSD (Tong et al., 
2000; Westerterp et al., 2008). As such we are not advocating that treatments with 
tolerable side effects be replaced with MSD, but rather aim to illustrate the 
potential use and development of MSD for contexts distinct from cancer therapy. 
Better understanding of the functional modifications caused by MSD in vivo may 
enable appropriate application to other diseases in the future. 
6.2 Future directions 
 
The current study provides some evidence that the immune system is functionally 
altered by MSD therapy and paves the way for continuing investigations in both 
BMMØ and CTL. Some, but not all, of the possible interactions leading to 
depressed cytokine production in BMMØ by paclitaxel were assessed in the 
current study. Future research examining the signalling molecules, transcription 
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factors and mRNA transcript levels in LPS stimulated, paclitaxel-treated 
BMMØ may help determine the functional cellular level at which cytokine 
production is blocked by MSD. Further, visualising cytokine transport and release 
from BMMØ treated with MSD or DSD could identify how microtubule-dependent 
transport mechanisms are involved in cytokine production.  
 
Numerous questions regarding the effects of MSD on CTL function in vitro and in 
vivo provide potential avenues of future research. Firstly, while murine CTL 
function is not inhibited in CTL treated with MSD (this thesis & Knox et al., 1993), 
exactly how lytic granules can traffick to the IS in CTL with an aberrant 
microtubule network remains unclear. Modified polarisation microscopy has been 
used to visualise the interaction of lytic granules with microtubules in live cells 
(Poenie et al., 2004), and this technology may be useful in determining how CTL 
can deliver lytic granules to TC when treated with MSD in vitro. Secondly, it would 
be of great interest to extend the in vivo component of this project and determine 
if peloruside or other MSD inhibit CTL-mediated cytolysis in vivo to the same 
extent as Taxol. Lastly, the question of how CTL-mediated cytolysis in vivo was 
altered by Taxol warrants further investigation. Flow cytometric assessment of 
CTL and TC surface phenotype and tissue distribution may provide basic 
information about how the cells can interact following MSD administration. 
Further, using visualisation techniques such as multiphoton intravital microscopy 
as used by Mempel et al. (Mempel et al., 2006) could allow for clear observation 
of how CTL and TC interact in vivo in mice treated with MSD.  
6.3 Final Conclusions 
 
This project aimed to understand the immunological implications of MSD therapy 
with specific regard to immune-mediated exocytosis. The results of this thesis can 
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be summarised in two statements. First, LPS-activated BMMØ production of 
TNF-α and NO is likely to be inhibited at a functional cellular level. Second, 
paclitaxel and peloruside do not alter CTL-mediated cytolysis, degranulation or 
IFN-γ production in vitro; whereas paclitaxel confers an inhibitory effect on CTL-
mediated cytolysis in vivo. This project is the first to examine the in vitro effects of 
peloruside on interphase CTL processes. It is also the first to show inhibition of 
CTL-mediated cytolysis in vivo by Taxol. The results of this thesis demonstrate 
that paclitaxel can functionally repress components of the immune system and 
suggest that patients undergoing MSD therapy may be unable to fight infection 
long before the anti-mitotic effects of MSD are apparent. 
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 Appendices 
 
Appendix A: Recipes 
 
Phosphate Buffered Saline (PBS): 
Sterile double distilled water with: 
Na2HPO4 8.7 mM 
NaH2PO4 1.3 mM 
NaCl  145 mM 
 
FACS buffer:  
2% FCS 
0.1% Sodium Azide 
97.9% PBS. 
 
Complete T cell Medium (CTCM) – Medium for MØ work: 
85.9% Dulbecco‟s Modified Eagle Medium (dMEM; Invitrogen) 
10% FCS 
1%HEPES (1 M) (Sigma) 
1%L-Glutamine (200 mM) (Invitrogen) 
1% Penicillin-Streptomycin (Penstrep; 100000 U/mL, 10000 g/mL respectively; 
Invitrogen) 
0.1% β-Mercaptoethanol (1000 x 55 mM; Invitrogen) 
1% Non-essential Amino Acids (10 mM 100x;Invitrogen) 
 
Handling medium - For MØ work: 
96% dMEM; 
3% HEPES; 
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1% PenStrep. 
 
Complete Iscove’s Modified Dulbecco’s Medium (cIMDM) – Medium for CTL 
and BMDC work: 
93.9% Iscove‟s Modified Dulbecco‟s Medium (IMDM; Invitrogen) 
5% FCS 
1% Penstrep 
0.1% β-Mercaptoethanol 
 
Freezing Medium – For cell storage: 
90% DMSO (Sigma) 
10% FCS 
 
Greiss Reagents: 
 A: 1% w.v Sulphanilamide in 2.5% phosphoric Acid 
 B: 0.1% w/v N-(1-naphthyl) ethylenediamine in 2.5% phosphoric Acid 
 128 
Appendix B: Antibodies: 
 
Streptavidin-CyC (BD Bioscience) 
Anti-I-Ab-PE (BD Bioscience) 
Anti-CD11b-Fitc (BD Bioscience) 
Anti-CD107a-Fitc (BD Bioscience) 
Anti-CD8a-Cyc (BD Bioscience) 
Anti-Vβ5.1/5.2-PE (BD Bioscience) 
Anti-CD44-AP (BD Bioscience) 
Anti-CD62L-AP (BD Bioscience) 
IgG2-α-Fitc (BD Bioscience) 
IgG2-α-PE (BD Bioscience) 
IgG2-α-Cyc (BD Bioscience) 
Anti-F4/80-biotin (Serotec, Oxford, UK) 
Anti-alpha-tubulin-IgG (Abcam) 
Alexafluor 488 polyclonal anti-rabbit IgG (Invitrogen) 
Anti-Vα2-Fitc (eBioscience, San Diego, CA, USA) 
Anti-CD45.1-APC (eBioscience) 
Anti-mouse-CD16/32 (FcR block) (eBioscience) 
 
